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Abstract 
Pseudomonas aeruginosa is a common opportunistic pathogen which is responsible for more than 
11% of nosocomial infections including urinary tract infections (UTI’s), bacteraemia, pneumonia and 
soft tissue infections. Little is known about P. aeruginosa associated infections in burn wound patients 
in South Africa, and in particular at Tygerberg hospital. Burn wound patients are highly vulnerable to 
infections due to natural defence destruction.  P. aeruginosa has the ability to form a biofilm and 
cause persistent biofilm associated infections. The biofilm acts as a protective layer defending 
organisms against the environment, host immune system and antibiotic treatment. P. aeruginosa 
infections have a mortality rate of 40-50% in burn wound patients. 
This study aimed to determine the population structure of P. aeruginosa isolated from the burns unit 
and burns ICU in comparison to isolates from other wards at Tygerberg hospital, to investigate their 
ability to form biofilms and to determine the impact of various antibiotics on biofilm formation. P. 
aeruginosa isolates from blood cultures, swabs and tissue specimens from adult and paediatric 
patients at Tygerberg hospital were collected from February 2015 to March 2016. Forty isolates from 
the burns unit and 40 isolates from outside the burns unit were used for the study. Multiple locus 
variable number tandem repeat analysis (MLVA) was used for strain typing. Biofilm formation was 
assessed by crystal violet staining. The strength of biofilm formation of the isolates was determined 
after a 12h incubation period and the effects of varying concentrations of four different classes of 
antibiotic on biofilm formation was determined over a 24 hour period.  
Forty two different MLVA types were described, of which ten were assigned to two or more isolates. 
Thirty two MLVA patterns were unique to a single isolate.  MLVA type 1 was the most abundant 
MLVA type; 60% of the isolates from the burns unit and burns ICU were type 1. The predominance of 
a single MLVA type within the burns unit implies nosocomial transmission within the burns unit. 
Greater diversity was observed outside the burns unit. P. aeruginosa appeared to form multiple 
biofilm formation patterns. Three distinct patterns of biofilm formation could be described after 10 
hours incubation. These patterns did not correlate with MLVA type. The effect of exposure to four 
antibiotics (cefepime, ciprofloxacin, imipenem, and gentamicin) on biofilm formation over time was 
shown to differ between organisms with early and late onset biofilm formation patterns, but is not 
predicted by MLVA type. The mechanisms of action of the antibiotics also did not seem to predict the 
response since two antibiotics with the same mechanism of action (cefepime and imipenem) had 
different biofilm formation patterns. 
Increased knowledge of the P. aeruginosa population structure and biofilm forming ability in this 
patient group, and enhanced understanding of the effect of antibiotic treatment on biofilm formation 
may enable improvements in transmission prevention, the selection and use of antibiotics for 
treatment and, ultimately, improve patient outcome. 
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Abstrak 
Pseudomonas aeruginosa is ‘n algemene opportunistiese patogeen wat verantwoordelik is vir meer 
as 11% van hospitaalinfeksies wat urienweginfeksies, bakteremie, longontsteking en sagteweefsel 
infeksies insluit. Daar is min inligting beskikbaar rondom P. aeruginosa infeksies in 
brandwondpatiënte in Suid Afrika, spesifiek in Tygerberg hospital. Brandwondpatiënte is hoogs 
vatbaar vir infeksies as gevolg van die vernietiging van hul natuurlike verdedigingstelsel. P. 
aeruginosa het die vermoë om ‘n biofilm te vorm en ‘n voortdurende biofilmgeassosieerde infeksie te 
veroorsaak. Die biofilm tree op as ‘n beskermingslaag wat die organismes beskerm teen die 
omgewing, die gasheer se immuunstelsel en antibiotiese behandeling. P. aeruginosa is 
verantwoordelik vir ‘n 40-50% sterftesyfer in patiënte met brandwonde. 
 
Hierdie studie is daarop gemik om die bevolkingstruktuur van P. aeruginosa, geisoleer uit die 
brandwondeenheid en brandwond intensiewesorgeenheid te vergelyk met isolate van ander eenhede 
in Tygerberg Hospitaal ten opsigte van hul vermoë om biofilms te vorm en die effek van antibiotika op 
biofilmvorming. P. aeruginosa isolate was ingesamel van bloedkulture, deppers en weefsel monsters 
van volwasse en pediatriese patiënte in Tygerberg hospital oor die tydperk van Februarie 2015 tot 
Maart 2016. Veertig isolate vanuit die brandwondeenheid en buite die brandwondeenheid 
onderskeidelik was gebruik in die studie. Multi lokus veranderlike aantal tandem herhaling ontleding 
(MLVA) was uitgevoer om stamtipering te doen.  Die vorming van die biofilms was bepaal met 
kristalvioletkleuring na ‘n 12-uur inkuberingsperiode, terwyl die effek wat vier antibiotika met 
verskillende konsentrasies en meganismes van werking oor ‘n 24-uur inkubasieperiode bepaal was. 
 
Twee-en-veertig verskillende MLVA tipes was geidentifiseer waarvan tien van die tipes twee of meer 
organisme besit. Twee-en-dertig MLVA patrone was uniek en het slegs een organisme besit. MLVA 
tipe 1 was die volopste; sowat 60% van brandwondeenheid en brandwond intensiewesorgeenheid 
isolate het aan MLVA tipe 1 behoort. Die oorheersing van hierdie MLVA tipe binne die 
brandwondeenheid/intensiewesorgeenheid impliseer dat daar wel oordrag binne-in die eenheid 
plaasvind. Daar was meer stamdiversiteit buite die brandwond eenheid. P. aeruginosa het drie 
verskillende biofilm patrone gevorm na 10 ure van inkubering waarvan daar geen ooreenstemming 
was tussen verskillende MLVA tipes nie. Die invloed van vier verskillende antibiotikas (cefepime, 
ciprofloxacin, imipenem en gentamicin) op die vorming van ‘n biofilm het getoon dat die aanvanklike 
hoeveelheid biofilm wat ‘n organisme vorm ‘n groot invloed op die werking van antibiotika het en dat 
daar ook geen ooreenkoms is tussen die biofilmvorming van organismes van dieselfde MLVA tipe. 
Die meganismse van aksie het ook geen merkwaardige impak getoon nie aangesien twee antibiotikas 
wat dieselfde aksie toon (cefepime and imipenem), biofilmvorming verskillend geaffekteer het. 
 
Verhoogde kennis van die P. aeruginosa bevolkingstruktuur en biofilmvormingsvermoë in hierdie 
groep pasiënte en ‘n verbeterde begrip van wat die effek van antibiotikabehandeling op biofilms is 
mag help om die uitkomste van gereelde oordrag en kliniese behandeling te verbeter.  
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Chapter 1 – Literature review 
1.1 Introduction 
 
Pseudomonas aeruginosa is a Gram-negative bacterium which was first discovered in 1882 
by the chemist Carle Gessard.[1][2]  This organism, which has a genome size of 5.2 to 7.1 
Mbp, can be acquired from the environment and can be found in multiple habitats including 
soil, marine habitats and commonly in plants.[3][4] The organism is known to cause 
opportunistic infections which are often health-care associated. P. aeruginosa can cause 
chronic and lethal infections amongst immune-compromised individuals and results in more 
than 11% of nosocomial infections.[4][5]  Infections can include urinary tract infections (often 
associated with urinary catheters), bacteraemia, respiratory infections (pneumonia) 
commonly found in cystic fibrosis patients and soft tissue infections linked to burn wounds, 
as well as burns sepsis that causes high morbidity and potential mortality.[3][6]  
Patients with severe burn wounds are prone to bacterial infections due to the physical 
destruction of the skin barrier, allowing colonising organisms within the sweat glands and 
hair follicles to cause infection. The majority of burns patient infections are due to Gram 
negative organisms, specifically Acinetobacter, P. aeruginosa, and Klebsiella pneumoniae. 
P. aeruginosa is one of the leading organisms causing infections in patients with burn 
wounds and is a major problem in hospitals due to patient to patient transmission.[7][8] P. 
aeruginosa was found to be responsible for 17.7% and 12.3% of infections in the ICU burn 
wards and common burn ward respectively in a study done in China.[8] A study has also 
shown that P. aeruginosa is responsible for the majority of burns patient infections in the 
United States.[7] The mortality rate of burn wound patients with P. aeruginosa infections can 
be up to 40-50%.[7] 
It is often difficult to treat and eliminate infections caused by P. aeruginosa due to its intrinsic 
resistance; meaning a natural resistance to a few broad spectrum antibiotics which are not 
able to enter the cell due to the low permeability of the outer membrane of the organism. 
This, in conjunction with efflux pump regulation, aids in antibiotic resistance.[9] P. aeruginosa 
also has the ability to form biofilms in a variety of environments and to develop resistance to 
antibiotics and disinfectants. Biofilms, which are bacterial cells grouped together and 
surrounded by an extrapolysaccharide matrix, are commonly found on wound tissue, body 
surfaces, lungs, as well as abiotic surfaces such as medical devices namely ventilators, 
catheters, joint and organ replacement parts.[10] Organisms within a biofilm have been shown 
to be less sensitive and some totally resistant to antibiotics and also to the immune 
system.[11][12]  
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Developing drug resistance is a major problem in the clinical environment, especially in P. 
aeruginosa where increasing resistance can lead to multidrug resistance (MDR).[13] Drug 
resistance, together with biofilm formation, can result in recurring infections which are nearly 
impossible to treat. Research has shown that factors contributing to MDR include using the 
incorrect antibiotic and/or concentration of drugs as well as environmental stress.[14–16] A 
study revealed that MDR has been shown to emerge more easily during antibiotic therapy 
when treating with a single antibiotic (4.4%) than when using combination therapy (3.1%).[17] 
The same study also revealed that MDR infections are more likely to occur in the ICU setting 
when a patient is on excessive fluoroquinolone treatment such as ciprofloxacin. To avoid the 
development of MDR strains one needs to apply suitable infection control methods and 
avoid unnecessary use of broad spectrum antibiotics.[16]  
There is a need for the rapid identification, treatment and prevention of transmission of P. 
aeruginosa in hospitals. This organism is a rapidly developing problem due to biofilm 
formation and the development of MDR. Patients with burn wounds are more susceptible to 
infection and P. aeruginosa is frequently the most abundant isolate isolated from the burns 
unit.[18] 
1.2 P. aeruginosa strain typing 
 
Molecular typing methods are used to distinguish between bacterial species and/or between 
different strains of the same species and have been expanding due to developing 
technologies.[19] Typing methods such as serotyping have long been used for P. aeruginosa 
strains but are known to be less successful when typing mucoid strains which are commonly 
found in patients with pulmonary infections. Molecular typing methods for the analysis of P. 
aeruginosa isolates provide higher discrimination compared to other phenotypic tests and 
are also highly reproducible.[20] Molecular typing methods can be easy, inexpensive and 
rapid tools for molecular epidemiological analysis and outbreak investigations. Common 
molecular techniques that are being used include pulsed field gel electrophoresis (PFGE), 
multi-locus sequence typing (MLST), ribotyping, restriction fragment length polymorphism 
DNA analysis (RFLP), random amplified polymorphic DNA assays (RAPD), amplified 
fragment length polymorphism (AFLP) and multiple locus variable number tandem repeat 
analysis (MLVA).[21][22] Strain typing of P. aeruginosa isolates from burn wounds has shown 
that the majority of isolates from the same ward are of the same strain. A study found that 
83% of patients acquired a P. aeruginosa infection during hospitalisation within a burns ward 
while two distinct genotypes were responsible for 60% of the burn wound patient 
colonization.[23] 
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1.2.1 Pulsed field gel electrophoresis ) 
 
PFGE is classified as the gold standard for strain typing since the discriminatory power is 
very high and it is also a inexpensive method. However, the method remains laborious and 
has low reproducibility as results are often difficult to compare to other databases from other 
studies.[24] PFGE works on the basis of restriction endonuclease digestion of the entire 
genome with restriction enzymes such as SpeI and XbaI, after which the DNA fragments are 
separated on an agarose gel by means of a changing electrical current.[25] The changing 
electrical current allows the separation of large DNA fragments by changing the direction of 
the flow and helping large fragments to sieve through the pores. The fragmented bands can 
be visualized generating a unique pattern for each species or strain.[26] A limitation of PFGE 
is that it has low resolution when it comes to distinguishing similar band sizes. PFGE is 
becoming less frequently used because PCR and sequencing based methods are becoming 
easier, inexpensive and more accessible.  
1.2.2 Multi-locus sequence typing 
 
MLST involves the amplification and sequencing of 450 to 500bp fragments of up to seven 
housekeeping genes. Each allele, which is a variant form of a gene, has a unique sequence. 
The specific alleles for each of the genes can be combined to generate a specific MLST 
profile. Loci commonly used for MLST of P. aeruginosa include acsA, aroE, guaA, mutL, 
noD, ppsA, and trpE.[2][25] MLST is very reproducible and the results are easy to compare to 
other databases such as http://pubmlst.org and www.mlst.net since the method is universal, 
however MLST is very expensive, laborious and time consuming.[26] 
1.2.3 Ribotyping 
 
Ribotyping focuses on the 16S, 23S and 5S ribosomal RNA genes which are conserved 
regions in all bacteria. Ribotyping works on the basis of restriction endonuclease digestion of 
the entire genome. The DNA fragments can then be separated by means of gel 
electrophoresis according to size and the fragments that contain a piece of the ribosomal 
operon are transferred and visualised by southern blotting through hybridisation with a 
radiolabelled ribosomal operon probe.[27][28]  
1.2.4 Restriction fragment length polymorphism DNA analysis  
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RFLP involves the use of restriction enzymes such as EcoRI to generate DNA fragments 
which are separated by gel electrophoresis based on size. Southern blotting followed by 
hybridisation with specific probes, is used to identify sequence variation between strains. 
These fragments sizes vary between organisms. The fragment will be classified as a RLFP 
when the size differs between individuals. This method has high reproducibility and 
discriminatory power, but  is time consuming and can be expensive.[29][30] 
1.2.5 Random amplified polymorphic DNA assays  
 
RAPD assays amplify a number of fragments using a single pair of non-specific primers that 
are roughly 10bp long. Amplification is performed at a low annealing temperature so that 
mismatch pairing can occur. Amplicon sizes normally range between 0.1 kb and 3 kb. 
Amplicons are separated and visualised using gel electrophoresis. RAPD has lower 
discriminatory power than PFGE but is an easy and cheap alternative. The reproducibility of 
this method remains low due to sensitivity to different reagents and machines as well as the 
low melting temperatures used during amplification.[26][31]  
1.2.6 Amplified fragment length polymorphism . 
 
This method works on the basis of cutting genomic DNA with EcoRI or Tru9I restriction 
enzymes followed by PCR after adapters have been added to one end of the cut 
fragments.[32] The fragments containing the adapters will be amplified with primers 
corresponding to the adapters. Fragments are labelled with fluorescent PCR primers for 
easier detection and visualisation with the aid of an automated DNA sequencer. AFLP can 
assist in distinguishing between strains and determining the corresponding genetic 
relatedness. AFLP is reproducible with high discriminatory power but the method is laborious 
and expensive.[26] 
 
1.2.7 Multiple locus variable number tandem repeat analysis . 
 
Multiple locus variable number tandem repeat analysis (MLVA) is a genotyping method 
using variable number tandem repeats (VNTRs). This method can be performed at low cost, 
produces a lot of information, delivers high discriminatory power as well as reproducibility 
and can be used for the identification of a number of strains from the same species.[33] It was 
initially used for human DNA fingerprinting and then developed for use in bacterial genomes. 
This method is based on the principle that each strain contains a different number of 
sequence repeats at specific loci. The number of repeats can be determined by the size of 
the amplified product (allele) which can be compared to other strains and enables unique 
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identification.[34] The repeats can be amplified by attaching locus specific primers which flank 
the repeat region.[20] VNTRs include microsatellites (smaller than 9bp) as well as 
minisatellites (larger than 9bp).[35] P. aeruginosa has a number of VNTRs which can be 
combined and used for unique strain identification.  
1.3 Antibiotic resistance in P. aeruginosa.   
  
MDR P. aeruginosa is a major developing problem since it causes persisting infections in 
hospitals and high rates of mortality. Organisms use different mechanisms to counter 
antibiotic activity and antibiotic resistance can be classified in three types namely intrinsic, 
acquired and adaptive resistance.[36] Intrinsic resistance can be explained as the organism’s 
natural resistance mechanisms without any previous exposure to antibiotics. Intrinsic 
resistance mechanisms include the semi-permeable outer membrane of Gram negative 
bacteria which slows down the entry of small hydrophilic antibiotics such as β-lactams and 
quinolones, efflux pumps which actively pump antibiotic out of the cell and the production of 
intrinsic periplasmic β-lactamases.[36] Acquired resistance is derived from exposure to 
antibiotics which results in selection of organisms with chromosomal mutations which 
mediate antibiotic resistance.[37] Acquired resistance can also be gained through genetic 
elements such as plasmids, transposons, interposons and integrons by horizontal gene 
transfer. Gram negative bacteria in particular use several acquired resistance mechanisms 
to counter the action of antibiotic therapy (Figure 1.1). Adaptive resistance is gained from 
environmental (physical and chemical) changes and growth circumstances of the bacteria 
which will then trigger reversible regulatory responses in the cell.[36],[38] Factors such as sub 
MIC concentrations of antibiotics, pH, rapid temperature changes, DNA stress, cations and 
nutrient deficiency are all inducers of adaptive resistance.[38] Sub inhibitory concentrations of 
ciprofloxacin are known to cause gene dysregulation.[39] Heat shock can induce 
aminoglycoside resistance while DNA stress induces fluoroquinolone resistance.[40] 
 
 
 
 
.  
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Figure 1.1:  Acquired resistance mechanisms in Gram negative bacteria. Gram 
negative bacteria use at least eight mechanisms, mediated by antibiotic resistance gene 
containing plasmids as well as chromosomal mutations, to counter the effects of antibiotics. 
Resistance mechanisms include porin loss, production of β-lactamases, efflux pump 
overexpression, modifying antibiotics, target mutations, ribosomal mutations, 
lipopolysaccharide mutations and metabolic bypass. Source: Peleg et al., (2010).[41] 
 
1.3.1 P. aeruginosa antibiotic resistance mechanisms. 
 
P. aeruginosa uses a number of resistance mechanisms to counter antibiotic effects (Table 
1.1). Antibiotics such as β-lactams, namely penicillins, cephalosporins, carbapenems and 
monobactams, and other major antimicrobials such as aminoglycosides, fluoroquinolones 
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and polymyxins are generally suitable for the treatment of P. aeruginosa but could become 
ineffective after mutations occur or resistance mechanisms are acquired.[16] Common 
resistance mechanisms of P. aeruginosa include efflux pump regulation, mutations and 
modified enzymes.[42] 
Table 1.1: P. aeruginosa mechanisms of resistance. P. aeruginosa can acquire several 
mechanisms to counter antibiotic effects. Source: Hirsch et al., (2011).[42] 
Resistance 
mechanism/mutation 
Components involved 
Antibiotic classes/agent 
affected 
Overexpression of 
RND-type multidrug 
efflux pump 
MexAB-OprM 
MexCD-OprJ 
MexEF-OprN 
Macrolides, aminoglycosides, 
sulphonamides, fluoroquinolones, 
tetracyclines, β-lactams 
Porin deletions OprD imipenem, meropenem 
β-lactamases PSE-1, PSE-4 
AmpC 
Metallo-β-lactamases 
Penicillins, Third generation 
cephalosporins, piperacillin, 
carbapenems 
Aminoglycoside 
modifying enzymes 
Acetyltransferases 
Nucleotidyltransferases 
Phosphotransferases 
Aminoglycosides 
16S rRNA methylase rmtA, rmtB, armA genes Aminoglycosides 
Quinolone resistance 
determining region 
gyrA, gyrB, parC, parE Fluoroquinolones 
 
P. aeruginosa contains multidrug efflux systems (MexAB-OprM and MexXY-OprM) which 
together with inactivating enzymes pump antibiotics such as fluoroquinolones, penicillins, 
cephalosporins, macrolides and sulphonamides across the Gram negative membrane and 
simultaneously degrade them.[43] The up-regulation of MexAB-OprM can result in these 
antibiotics becoming ineffective. Mutations in oprD or its regulatory regions result in the 
down regulation or loss of the OprD outer membrane porin, preventing uptake of 
carbapenems and resulting in resistance, specifically to imipenem and meropenem.[44][45] The 
absence of the OprD membrane porin in combination with overexpression of efflux pumps 
results in increased resistance to some carbapenems.[9]  
Enzymes such the β-lactamases, PSE-1, PSE-4, AmpC and metallo-β-lactamases, break 
down β-lactam antibiotics such as penicillins, cephalosporins and carbapenems. 
Overexpression of the AmpC β-lactamase can result in resistance to mainly penicillin as well 
as cephalosporins.[46] Aminoglycoside modifying enzymes inactivate aminoglycosides by 
catalysing either the acetylation of an amino group or the adenylation or phosphorylation of a 
hydroxyl group in the antibiotic. 16S rRNA methylases play a significant role in countering 
antibiotic activity by inhibiting the activity of aminoglycosides. Aminoglycosides normally 
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interfere with protein synthesis by binding the 30S ribosomal subunits.[42] Mutations occurring 
in topoisomerases II and IV can lead to fluoroquinolone resistance.[47]  
 
1.4 P. aeruginosa biofilms.  
 
Bacteria such as P. aeruginosa can grow either in a planktonic, free floating form or as a 
biofilm attached to a surface. Biofilms are biologically active bacterial cells which are 
grouped together and surrounded by an extrapolysaccharide matrix (EPS).[48] The EPS 
makes up 75-90% of the biofilm and keeps the cells together and attached to a substrate, 
while the cells, which can consist of one or more bacterial species, make up 10-25% of the 
biofilm.[49][50]  Biofilms serve as a barrier which delays or even prevents antibiotics, other 
biocides, cationic antimicrobials and antimicrobial peptides from entering and affecting the 
organisms; and  protects against environmental factors. The biofilm protects organisms from 
harsh conditions such as extreme dryness and against oxidation.[51] Within a biofilm, 
communication between the cells can occur and impacts the regulation of expression of 
virulence factors and helps the organism  survive in a nutrient deficient environment.[50]  
Biofilms were first described by Antonie van Leuwenhoek in 1674 after taking scrapes from a 
tooth and describing aggregates of cells on the surface. It has been found that 99% of 
bacteria will be in a biofilm state at a certain point in their life cycle.[50] Biofilms can cause 
harmful side effects and commonly affect humans in a number of ways, for example food 
spoilage, corrosion, malodours, infections and pipe blockages. In hospitals nosocomial 
infections are commonly caused by instruments, drips, catheters and ventilators which are 
contaminated with biofilms.[50] Biofilms are also commonly associated with recurring 
diseases such as periodontal disease, endocarditis and osteomyelitis.[12] P. aeruginosa 
infections are common in burn wound patients and while this organism is associated with 
biofilm formation there is still evidence lacking as to whether biofilms are common in these 
patients. Apart from the negative effects of biofilms, they can also be useful in industry. 
Biofilms are being used in bioremediation, a process that involves using the biofilm to 
remove contaminants such as oil spills and purifying waste water.  
1.4.1 Biofilm structure 
The presence of a substrate as well as microbes is necessary for biofilm formation. The EPS 
of a biofilm consists of biomolecules (metabolites), exopolysaccharides, extracellular DNA 
(eDNA), lipids and a polypeptide mixture and forms the structure of the biofilm.[52][53] P. 
aeruginosa can produce three types of polysaccharides namely alginate, pellicle (Pel) and 
polysaccharide synthesis locus (Psl) polysaccharide.[54] At least one of the two main 
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polysaccharides, Psl polysaccharide and Pel, is necessary for the first structural 
developmental stages of a biofilm, while alginate is not essential for biofilm development.[55]  
The psl operon (polysaccharide synthesis locus) contains 15 coding genes that are involved 
in the production of Psl polysaccharide, which contributes to the attachment of cells to other 
cells as well as to surfaces, and especially to mucin surfaces found in airways (Figure 
1.2).[54] Psl polysaccharide contributes to the maintenance of a biofilm after it has formed by 
supporting the structure. Psl polysaccharide is not a vital component for biofilm formation in 
all strains, except for strains PAO1 and ZK2870.[56] 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The psl and pel operons. Each operon contains different genes coding for 
enzymes which assist in biofilm formation. The enzymes being produced are localised in the 
following areas of the cell: M-membrane, C-cytoplasm, S-secreted. Source: Ryder et al., 
(2007)[54]. 
 
The pel operon contains 7 coding genes and plays an important role in the biofilm structure, 
especially in the PA14 and PAK Pseudomonas strains since they don’t produce Psl 
polysaccharide (Figure 1.2).[54] The glucose rich matrix polysaccharide, pellicle, is produced 
by enzymes encoded by the pel locus. Pel polysaccharide production is regulated by c-di-
GMP, a  monophosphate messenger.[57] The P. aeruginosa strain PAO1 is known to possess 
both the pel and psl operons.[56]  
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Alginate is an acetylated polymer made up of mannuronic and guluronic acid which is 
overproduced as a result of a mutations in the mucA gene.[58] These mutations induce the 
regulation, therefore inducing expression of the anti-sigma factor AlsT, which is an essential 
factor for the production of alginate, thereby enhancing the expression of the alginate 
producing operon.[58] Alginate is not essential for biofilm formation and some strains such as 
PAO1 and PA14 produce minimal amounts. Some P. aeruginosa strains have the ability to 
grow either in a mucoid or non-mucoid state. These two states differ in the composition of 
their polysaccharide matrix; the mucoid state resulting from overproduction of alginate.[59] 
eDNA plays an important role in the biofilm matrix and is necessary during the initial 
formation of a biofilm.[60] P. aeruginosa is known to release eDNA and it is speculated that it 
is released through vesical formation rather than cell death.[61] In the absence of eDNA, 
biofilms are easily affected by detergents such as sodium dodecyl sulfate. eDNA also aids in 
the twitching motility for the enlargement of a biofilm by maintaining coherent cell 
alignments.  eDNA can  be used as a source of nutrients for bacteria during starvation and 
can aid in cell to cell connections.[62] 
 
1.4.2 Biofilm development 
 
According to Garret et al.,(2008)[50] and Rasamiravaka et al.,(2015)[63] there are three 
important stages for the initial development of a biofilm (Figure 1.3), starting with free cells 
attaching to a surface forming a thin film (biotic or abiotic) in a process called adhesion after 
approximately 2 hours. Secondly, free floating cells will cohere irreversibly to these cells in a 
process called cohesion, 8 hours after the initial inoculation. Thirdly, micro colonies will arise 
by forming polymer bridges between each other, which occurs 14 hours after the initial 
inoculation. These three stages form the first two phases of a biofilm, namely the lag (step 
one and two) and exponential phases (step 3). After these initial biofilm formation steps, 
stationary phase will be reached when the rate of cells being formed is equal to the amount 
of cells dying. During the stationary phase of a biofilm the cells will start communicating 
through quorum sensing where auto inducers are produced for the development of unique 
gene expression changes which contribute to antibiotic and biocide resistance. The final 
phase of the biofilm cycle is the death phase (breakdown of biofilm) which results in the 
release of cells into planktonic growth for the formation of new biofilms on other 
substrates.[50] 
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Figure 1.3: Biofilm life Cycle. 1. Free floating cells (planktonic cells) will attach to a surface 
(adhesion). 2. Cell to cell cohesion will occur. 3. Cells will proliferate on the surface and form 
a biofilm by producing an extracellular polymeric substance. 4. After the biofilm has matured 
biofilm growth will come to a halt, the cell will die off and some cells will disperse back to free 
floating cells (stationary and death phases).  
Source: http://mpkb.org/home/pathogenesis/microbiota/biofilm.[64] 
 
During the first stage of biofilm formation a conditioning layer is formed. This layer acts as 
the foundation of the biofilm. Other molecules or particles can attach to the surface and form 
part of the conditioning layer. This layer will aid in the attachment of the bacteria and carry 
the necessary nutrients for biofilm formation and growth. Cells will attach to the conditioning 
layer either reversibly or irreversibly. Planktonic cells that attach reversibly usually attach 
with weak forces such as van der Waals forces, steric interactions and electrostatic 
interactions. Some cells that are bound reversibly will bind irreversibly by countering the 
repellent forces using their flagella, fimbriae or pili, staying attached to the surface.[50] 
As the attachment stage progresses the attached cells will divide and differentiate. The new 
cells being formed will grow outwards and upwards to form clusters.[65] This process will 
allow the biofilm to form a mushroom-like structure. It is hypothesized that this structure 
allows nutrients to be transferred to the bottom of the biofilm.[56]  
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An exponential growth phase will be reached where the cell population will increase rapidly. 
Stronger bonds between cells will be initiated by the cells through the release of 
polysaccharide intercellular adhesion (PIA) polymers as well as the formation of cationic 
interactions.[66]  
After the rapid growth phase of the biofilm the cells will go into the stationary phase where 
the number of cells being formed will be equal to the amount of cells dying in the biofilm. 
Cells will start to disperse with the help of alginate lyase which will break down the EPS.[67] 
This process will aid in cells being released into a planktonic state to attach to new surfaces 
and to start a new biofilm. The genes coding for the flagellum are also up regulated to 
enhance cell dispersion.  
Biofilm formation is controlled by physical, chemical and biological processes.[50] Numerous 
environmental conditions will affect the formation, structure and maintenance of a biofilm. 
When the pH of the environment differs greatly from the pH of the cells it affects the function 
of the membrane proton motors and causes a passive influx of the protons and can result in 
biocidal effects, affecting the bacteria and altering biofilm formation. A rapid change in 
environmental pH will cause more damage than a slow change since it has been shown that 
cells adapt to this change by synthesising and adjusting the necessary proteins for counter 
action.[68]  
The correct temperature is necessary for the organism to increase its nutrient intake to allow 
rapid growth and biofilm formation.[68] Temperature is also important for enzyme activity 
which can be linked to cell development and biofilm formation. Temperatures lower or higher 
than the optimal required temperature will result in little to no growth since this will slow 
down or stop enzyme activity as well as metabolic activity.[50] Temperature also has an effect 
on compounds found close to the cell or in the cells that are involved in cell development. In 
a previous study it has been shown that a lower temperature can reduce the likelihood of 
cells binding to a surface which is mainly due to the molecule (surface polymer) that is 
responsible for the attachment of the cell to a surface being reduced, while the temperature 
can also result in a smaller surface area for attachment.[50] Organisms may also have 
variable numbers of flagella at different temperatures. According to a study by Herald et al., 
(1988), bacteria such as Listeria monocytogenes have one flagellum at 35˚C while the 
number of flagella increases as the temperature decreases, for example at 10˚C the bacteria 
had several flagella.[69] Studies have also shown that higher temperatures increase the 
adherence of the organisms to a substrate making it more difficult for biofilms to be 
removed.[50] 
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1.4.3 Biofilm regulation  
 
Several systems regulate EPS production and thereby biofilm formation; the most important 
being the quorum sensing (QS) systems (Figure 1.4).[50][70] Quorum sensing is involved in 
cell to cell communication by producing signal molecules which regulate the production of 
virulence factors and help the organism with motility and biofilm formation.[71] There are three 
main QS systems found in P. aeruginosa namely las, rhl and Pseudomonas quinolone signal 
system (PQS).[72] The las and rhl systems are responsible for the production of two signalling 
molecules, N-(3-oxododecanoyl)-L-homoserine lactone and N-butanoyl-L-homoserine which 
play an important role in the formation of biofilms as well as the expression of virulence 
factors.[55],[63] Signalling molecules are produced as the population expands, and bind to 
target sites of transcriptional activators such as LasR or RhlR to regulate gene 
expression.[73][72] A third system, the PQS system is responsible for the formation of the 
Pseudomonas quinolone signal and is actively involved with the auto inducer molecules. 
Two additional two component systems, GacS/GacA and RetS/LadS are also involved in 
biofilm formation and growth. The two-component systems play an important role in the 
structure of a biofilm, virulence factor production and the overall fitness of the organism 
(Figure 1.4). These systems work on the basis of membrane associated sensor histidine 
kinases which track signals and changes in the environment of the organism. A stimulus will 
result in phosphorylation of the histidine kinase residue which will be carried over to the 
cytoplasmic response regulator, which can then regulate the expression of various genes. 
Stimuli affecting this mechanism include factors such as acyl-homoserine lactones (quorum 
signals), nutrients, and antibiotics.[74] An additional monophosphate messenger, c-di-GMP, is 
important for further biofilm formation enhancement by inducing Pel and alginate production. 
Each system influences the biofilm in a unique way.  
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Figure 1.4: The regulation of the P. aeruginosa biofilm. The formation of a biofilm is 
regulated by a number of regulatory genes which are responsible for the production of 
products and processes that are actively involved in biofilm formation. 1. Quorum sensing 
systems. 2. Two component systems. 3. Extra-polysaccharide production c-di-GMP 
regulation.  Source: Rasamaravika et al., (2015).[63]  
 
1.4.3.1 las system. 
 
The las system is made up of two transcriptional activator proteins namely LasR and LasI. 
LasR is a cognate regulator gene while LasI is responsible for the production of the auto 
inducer signalling molecule N-(3-oxododecanoyl)-L-homoserine lactone. When the signalling 
molecules bind to the transcriptional activator LasR, it will activate expression of genes such 
as lasB, lasA, apr and toxA, which are responsible for the production of virulence factors.[75] 
Without the presence of the las system a biofilm will appear flat and minimal changes will 
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occur in the biofilm; while detergents will have a bigger impact on  biofilm dispersal.[76] The 
rhl and PQS systems are also positively regulated by the las system.  
1.4.3.2 rhl system. 
 
The rhl system consists of two transcriptional activator proteins namely RhlR and RhlI. RhlR 
is a cognate regulator gene while RhlI is responsible for the production of the auto inducer 
signalling molecule N-butanoyl-L-homoserine.[77] As seen in Figure 1.4, the rhl system 
directly influences the biosynthesis of Pel polysaccharides by enhancing their production.[63] 
The swarming of cells and cell to cell contact is regulated by the rhl system for organized 
surface translocation.[78] Without the ability to move, biofilms will form unstable cell structures 
making the biofilm weak and sensitive to environmental stress or treatment. The rhl system 
is also responsible for the production of glycolipids called rhamnolipids. These glycolipids 
have several responsibilities during biofilm formation. Rhamnolipids are hypothesised to be 
responsible for the formation of micro colonies in biofilms, they are responsible for controlling 
cell to cell adhesion and cell to surface adhesion to form channels in the biofilm for 
molecules to “flow”. Mushroom shaped structures are formed with the help of these 
glycolipids which also help with the release and dispersion of cells from the biofilm. The 
production of two lectins is also regulated by the rhl system. These are LecA and LecB 
which are cytotoxic virulence factors.[79]  
1.4.3.3 PQS system 
 
A third system, the PQS system, produces Pseudomonas quinolone signalling molecule (2-
heptyl-3-hydroxy-4-quinolone) and primarily interacts with the auto inducer, acyl homoserine 
lactones.[71] The products formed by the pqsABCD and phsH genes aid in the production of 
PQS. The regulator, known as PqsR is essential for the production of PQS and regulates a 
number of genes active in this process.[80] This system is also responsible for the release of 
eDNA during biofilm development. The PQS molecule regulates a number of virulence 
factors of P. aeruginosa. PQS is commonly produced in the lungs of patients with cystic 
fibrosis. Studies have shown that PQS is actively involved in signalling between the las and 
rhl systems.[81] 
1.4.3.4. GacS/GacA system 
 
The GacS/GacA system is known to regulate virulence factor production and biofilm 
formation and is also an important regulator of quorum sensing in P. aeruginosa.[82] This 
system works as follows: the GacS (hybrid sensor kinase) will transfer a phosphate group 
over to the GacA regulator; which upregulates the small regulatory RNAs RsmZ and RsmY 
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which will bind to the RNA binding regulatory protein RsmA which aids in regulating the psl 
locus. The production of the autoinducers N-(3-oxododecanoyl)-L-homoserine lactone and 
N-butanoyl-L-homoserine is also influenced by the GacS/GacA system. The system can 
inhibit the production of these acyl-homoserine lactones (acyl - AHL), thereby inhibiting 
quorum sensing via the las and rhl systems. 
1.4.3.5 RetS/LadS system 
 
The RetS/LadS histidine kinases have an effect on the activity of GacS by regulating its 
phosphorylation and thereby influencing the production of the exopolysaccharide Psl.[83] 
RetS on its own will inhibit biofilm formation while LadS will counter this effect by inhibiting 
the activity of RetS. It has been shown that the RetS/LadS system regulates the expression 
of genes necessary for the organism to grow and colonize causing an acute infection; or 
developing a biofilm for a more sustainable infection.[74] This system not only regulates the 
production of polysaccharides Pel and Psl polysaccharide, but also regulates genes 
expressing virulence factors and involved in motility. 
1.4.3.6 c-di-GMP  
 
The production of Pel polysaccharide is regulated by the monophosphate messenger c-di-
GMP (bis-(3’-5’)-cyclic dimeric guanosine monophosphate) together with the pel operon. c-
di-GMP is produced by diguanylate cyclases (Figure 1.4). The polysaccharide alginate and 
Pel will be synthesised when c-di-GMP induces their production. This process occurs when 
c-di-GMP binds to proteins PelD or Alg44, which possess receptors for the monophosphate 
messenger, resulting in the production of individual polysaccharides and enhancing biofilm 
formation.[57] c-di-GMP is also known to improve the movement of bacterial cells which aids 
in the dispersion of the biofilm cells.[84] 
 
1.4.4 Gene expression in P. aeruginosa biofilms 
 
Gene expression profiles of bacteria in a biofilm differ significantly from those in planktonic 
growth, which contributes to antibiotic resistance, evasion of immune responses and 
expression of virulence factors.[11][36] Proteins active within a biofilm population undergo up 
and down regulation as antibiotics are introduced to the environment to counter the action of 
the antibiotic.[85] In P. aeruginosa, genes coding for the flagella or pili undergo down 
regulation when cells are in a biofilm, since they are not of use.[11] Further studies have 
shown that in a biofilm, genes such as tolA are actively expressed and can result in 
aminoglycoside resistance.[12] Cytochrome c oxidase activity is also repressed and can result 
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in reduced sensitivity to aminoglycosides.[86] Wild type P. aeruginosa strains contain the rpoS 
genes, which contributes to transcription by regulating the RNA polymerase sigma subunit. 
This gene is a known stress response regulator which aids in regulating genes to handle 
environmental stresses while it also plays a role in the formation and development of a 
biofilm.[11][87] Cellular stress, such as amino acid, carbon, nitrogen, phosphorus and iron 
shortages, as well as temperature stress will trigger the production of the alarmone, 
guanosine tetra- and penta-phosphate (p)ppGpp by the enzymes RelA and SpoT.[88] 
(p)ppGpp is responsible for mediating a stringent response which alters the expression of 
various genes and contributes to the formation of a biofilm and also to help the cell adapt 
from a growth phase to a survival phase.[71][36]  
1.5 Clinical impact of biofilms in P. aeruginosa 
 
Multidrug resistant P. aeruginosa is a rapidly developing problem in the clinical environment 
due to the spread of MDR organisms between patients, especially in the ICU. MDR is 
defined as resistance to one or more agents within at least three classes of antibiotics 
including aminoglycosides, penicillins, cephalosporins, carbapenems and 
fluoroquinolones.[42][89] Biofilms are important for the protection of the organism, promote 
persistence and provide an advantage to the organism’s wellbeing. A biofilm will protect the 
organism from the environment as well as physical and chemical factors such as antibiotic 
treatment and the host’s immune system.[12] Research has shown that organisms within a 
biofilm are more resistant to antibiotics. Resistance occurs at a hundred or even a thousand 
times the minimum inhibitory concentration (MIC) when compared to planktonic growth.[90] 
Biofilms show high resistance to antimicrobials which can be attributed to altered gene 
expression, external stress and unique biofilm structures.[36] Different strategies are being 
used to overcome the resistance mechanism of biofilms. This includes preventing the 
attachment of the organism to a surface, breaking down and disrupting a biofilm to assist the 
entry of antibiotics and preventing the maturation of the biofilm.[91][12]  
Biofilm forming strains can commonly be found on burn wounds and in cystic fibrosis 
patients. P. aeruginosa infections are found to be more difficult to treat and eradicate with 
antibiotics as the disease progresses which may be due to the development of a biofilm.[34] 
P. aeruginosa biofilms found in cystic fibrosis patients are impossible to fully eradicate during 
a pulmonary infection, even with aggressive antibiotic therapy which will only aid in slowing 
down the development of the disease.[92] Polysaccarides such as alginate have been proven 
to lead to the development of resistance against tobramycin. It is also speculated that 
alginate can protect organisms against environmental factors such as oxidative stress and 
the immune system.[93] During inflammation in the lungs of cystic fibrosis patients alginate is 
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released and can protect the organisms from phagocytes.[94] Alginate, which can result in 
mucoid growth in vivo also aids in the resistance of the cell to the host’s immune 
system.[95][54] Previous studies have shown that alginate plays a significant role in biofilm 
antibiotic resistance as the excessive production of alginate results in major changes to the 
morphological structure of the biofilm.[54][58] Treating mucoid Pseudomonas aeruginosa with 
alginate lyase to assist alginate breakdown results in increased sensitivity to gentamicin.[58] 
Although some bacteria appear to be resistant to antibiotics when growing in a biofilms, they 
have been shown to become susceptible when leaving the biofilm, suggesting that 
mechanisms other than mutations contribute to antibiotic resistance in a biofilms.[96] There 
are three main hypotheses that have been described for the antibiotic resistance of bacteria 
in biofilms. The first hypothesis involves the prevention of the antibiotic from entering the 
biofilm matrix or slowing down the process; such as for aminoglycosides. However 
penetration of certain antibiotics such as fluoroquinolones will not be altered by the structure 
of the biofilm.[12] There is indeed a limitation on this mechanism since the amount of 
antimicrobial binding proteins is limited and will thus result in further penetration of the 
antimicrobial when all binding proteins are occupied.[12] Secondly, the microorganisms may 
change or remove molecules or processes present in the environment which can influence 
the antibiotic activity. Factors such as pH,[97] oxygen[98], and the osmotic environment[99] can 
directly affect antibiotic susceptibility. When an organism stops growing due to insufficient 
nutrients or substrates, antibiotics can lose their effectiveness since some antibiotics such as 
penicillin only target growing organisms.[100] The third hypothesis describes cells that form a 
spore-like state with a decrease in metabolic activity and growth and can persist after 
antibiotic treatment since they are not actively targeted.[96][101] This can also be explained by 
nutrients not diffusing to the innermost part of the biofilm due to the outer organisms 
consuming it and none reaching the persister cells which become metabolically inactive.[36]   
According to Livermore et al.,(2002)[16] changes in multiple factors such as the up regulation 
of efflux pumps, down regulation of OprD as well as impermeability to aminoglycosides can 
increase resistance to multiple antibiotics. P. aeruginosa is known to cause high morbidity 
related persisting nosocomial infections due to developing multidrug resistance and biofilm 
formation in immunocompromised patients.   
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
   
20 
 
1.6 Problem statement 
Biofilm forming organisms cause persisting infections within the healthcare setting. In the 
clinical setting biofilm formation commonly occurs on wound tissue, body surfaces, lungs, as 
well as medical devices namely ventilators, catheters, joint and organ replacement parts.[10]  
Biofilms play a significant role in antibiotic resistance influencing the effects of antibiotic 
activity in different ways such as preventing penetration of antibiotics and reaching the cells 
within the biofilm.  
1.7 Aims & Objectives 
 
The aim of the study is to determine the population structure of P. aeruginosa in tygerberg 
hospital and to investigate the biofilm formation of thesis isolates and study the impact of 
common gram negative antibiotics on the formation of a biofilm.  
Objectives 
1. To determine the population structure of P. aeruginosa isolates from patients from the 
burns ward/ICU at Tygerberg Hospital in comparison to isolates from outside these wards.  
2. To determine the biofilm formation ability of these isolates. 
3. To determine the effect of common Gram negative antibiotics on the biofilm formation 
abilities of these isolates.  
The study will enable us to determine whether transmission occurs within the clinical setting 
which will allow the implementation of the necessary control measurements, if required. An 
improved understanding of the biofilm formatting ability of these isolates and the impact of 
antibiotic treatment on the formation of biofilms may lead to  improvements in the clinical 
treatment of P. aeruginose infections and thereby their outcome.  
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Chapter 2 – Strain typing 
2.1 Introduction  
Nosocomial infections play a major role in morbidity and mortality and commonly result in the 
spread of MDR organisms. Pseudomonas aeruginosa is responsible for 10% of nosocomial 
infections and is ranked the 4th most abundant pathogen acquired in hospitals.[102] Spread 
within wards, between immune compromised individuals and patients receiving 
chemotherapy, occurs regularly in the ICU (intensive care unit) and burns wards. P. 
aeruginosa is commonly associated with a range of infections and the risk of developing a P. 
aeruginosa infection increases as the length of stay increases.[103]  
The aim of this study was to determine the population structure of P. aeruginosa isolated 
from patients from the burns unit/ICU (burns unit and burns ICU) and to compare it to other 
P. aeruginosa isolates from Tygerberg Hospital. 
The population structure was determined using MLVA (multi locus variable number tandem 
repeat analysis). MLVA works on the basis of amplifying variable number tandem repeats 
(VNTRs) targeting polymorphic tandem repeat loci. P. aeruginosa is known to be tandem 
repeat rich.[20] The polymorphic tandem repeats were previously identified using a program 
for strain comparison, developed by Denoeud and Vergnaud to identify intergenic sequences 
which are tandemly duplicated and which can be found multiple times throughout the 
genome..[34] Primers were designed to flank the 5’ and 3’ VNTR tandem repeat regions to 
amplify the tandem repeat. As the number of tandem repeats at each locus can differ 
between different strains, different allele sizes result in different product sizes which can be 
visualized by means of gel electrophoresis, as seen in figure 2.1. The allele sizes can then 
be combined to create an MLVA pattern by assigning an allele repeat number to the different 
allele sizes and generating a repeat pattern specific to an MLVA type.[20] MLVA typing data 
can be added to the MLVA genotyping database MLVAbank for Microbes Genotyping for 
comparison between different studies. The database contains MLVA typing information of 
different organisms, including P. aeruginosa, from all over the world, and with all the 
described allele sizes. 
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Figure 2.1:  Representation of variable number tandem repeats at a specific locus. 
Each allele can have a different number of repeats which will result in a different size which 
can be visualized by means of gel electrophoresis. Source: Chen (2008).[104] 
 
Previous studies have shown that although MLVA typing is relatively stable, it has some 
drawbacks. It has been documented that some loci do not amplify in certain strains. This 
could be explained by the addition, deletion or even mispairing of repeats at a specific VNTR 
locus (partially or entirely) and occurs more frequently with microsatellites.[34] Repeat sizes 
larger than those previously described (more than 1.5kb) have been identified and may be 
explained by the presence of an IS element (insertion sequence) in the tandem repeat.[34] An 
IS element is a transposable element which normally codes for proteins aiding in the 
movement of the element within a genome, thus regulating transposition.[105] However, 
MLVA is an easy and rapid molecular strain typing method for the identification of related 
strains within a community. Compared to other molecular methods, it is relatively 
inexpensive and robust and has a high inter-laboratory reproducibility.[33]  
Accurate typing is necessary to determine the epidemiology of P. aeruginosa in Tygerberg 
Hospital. Identifying the strain types will help to describe transmission events and allow the 
implementation of precautions to avoid nosocomial transmission; which will assist in infection 
control in the hospital. Strain typing can also help to identify differences in virulence 
properties, such as biofilm formation, as described in chapters 3 and 4. 
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2.2 Materials and methods 
2.2.1 Sample collection and storage 
P. aeruginosa isolates were collected from the National Health Laboratory Service (NHLS) 
microbiology laboratory at Tygerberg Hospital (South Africa). Isolates were collected from 
February 2015 to March 2016 and included all P. aeruginosa isolates from blood cultures, 
pus swabs, tissue samples and aspirates from patients admitted to Tygerberg Hospital. 
Duplicate isolates from the same patient were not included. 
Species identification and antibiotic susceptibility testing were done by the NHLS routine 
diagnostic laboratory using the VITEK-2 automated platform (Biomerieux, France) in 
conjunction with disk diffusion susceptibility testing and other routine tests and interpreted 
according to the Clinical and Laboratory Standard Institute (CLSI) guidelines[106], as part of 
routine diagnostic procedures. Isolates were stored in MicrobankTM tubes (Pro-Lab 
diagnostics) at -80˚C, according to the manufacturer’s protocol.  
A total of 40 P. aeruginosa isolates obtained from patients within the burns unit/ICU and 40 
P. aeruginosa isolates from patients outside the burns unit/ICU were used for this study. All 
isolates from patients admitted to the burns unit/ICU were included. Selected isolates from 
outside the burns unit/ICU, representing all sample types over the full collection period, were 
included. The P. aeruginosa PAO1 (Harvard) strain was obtained from the National Institute 
of Communicable Diseases (NICD) and used as a control strain as the whole genome 
sequence and MLVA typing results for this strain are available. 
2.2.2 Bacterial culture conditions 
A Microbank bead vial containing stored culture at -80˚C was thawed and streaked out on 
TBA agar (tryptose blood agar, NHLS Greenpoint Media Laboratory) and incubated 
aerobically overnight at 37 ˚C. 
2.2.3 DNA extraction 
Crude DNA extraction was performed on all isolates. A loop full of a pure overnight culture 
was suspended in 300 µl of dH2O in an Eppendorf tube and vortexed for 30 seconds. The 
sample was placed in a heating block at 95 ˚C for 30 minutes and then placed directly at -80 
˚C for 30 minutes. The samples were thawed and centrifuged in a Spectrafuge 24D 
centrifuge (Labnet) at maximum speed, 15 600 x g (13 000 rpm), for 10 minutes to remove 
cell debris. DNA extracts were stored at -20 ˚C. 
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2.2.4 MLVA strain typing 
2.2.4.1 MLVA PCR 
MLVA analysis was done using 13 VNTR loci (ms77, ms127, ms142, ms172, ms211, 
ms212, ms213, ms214, ms215, ms216, ms217, ms222 and ms223) using specific primer 
sets (Table 2.1) as described by Vu-Thien et al., (2007).[34] PCR was performed using KAPA 
Taq ReadyMix PCR Kit (KAPA Biosystems) according to manufacturer’s conditions, with the 
exception of using KAPA2G Robust HotStart ReadyMix PCR kit (KAPA Biosystems) for 
ms213. The PCR master mix was made up as follows: 7.5µl KAPA Taq ReadyMix/KAPA2G 
Robust HotStart ReadyMix, 0.6µl of each primer (50pmol/µl) (2µM per reaction), 1µl 
template DNA and 5.9µl dH2O in a 15µl reaction. The PCR assays were performed on the 
Applied Biosystems Veriti Thermal Cycler (Thermo Fisher Scientific) or the ProFlex PCR 
system (Thermo Fisher Scientific). The cycling conditions used were as follows: an initial 
denaturation of 3 minutes at 95 ˚C, followed by 35 cycles of denaturation of 30 seconds at 
95 ˚C, annealing for 30 seconds at 55/60/62˚C and extension for 1 minute at 72˚C, followed 
by a final extension of 1 minute at 72 ˚C and hold at 4˚C until downstream analysis. Different 
annealing temperatures were used for different primer sets, as shown in Table 2.1.  
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Table 2.1: MLVA PCR and sequencing primers. The repeat unit size of each VNTR locus, 
the number of possible alleles at each locus and the repeat number of each allele, and the 
expected P. aeruginosa PAO1 product size are indicated. Adapted from Vu-thien et al., 
(2007)[34] and Youenou et al., (2014).[24] 
VNTR 
locus 
Primer name Primer sequence 
Tm 
˚C 
Repeat 
unit 
size 
(bp) 
No. of alleles  
(possible allele 
repeat numbers) 
PAO1 
product 
size 
(bp) 
ms77 ms77F GCGTCATGGTCTGCATGTC 
60 39 8(1-6; 1,5; 2,5) 442  ms77R TATACCCTCTTCGCCCAGTC 
ms127 ms127F CTCGGAGTCTCTGCCAACTC 
60 15 2(8-9) 210  ms127R GGCAGGACAGGATCTCGAC 
ms142 ms142F AGCAGTGCCAGTTGATGTTG 
60 115 10(1-7; 12; 2,5; 3,5) 890  ms142R GTGGGGCGAAGGAGTGAG 
ms172 ms172F GGATTCTCTCGCACGAGGT 
60 54 7(8-13; 8,5) 789  ms172R TACGTGACCTGACGTTGGTG 
ms211 ms211F ACAAGCGCCAGCCGAACCTGT 
60 101 9(2-9; 1,5) 663  ms211R CTTCGAACAGGTGCTGACCGC 
ms212 ms212F TGCTGGTCGACTACTTCGGCAA 
60 40 10(3-9; 11-12; 14) 522  ms212R ACTACGAGAACGACCCGGTGTT 
ms213 ms213F CTGGGCAAGTGTTGGTGGATC 
62 103 12(0-7; 9; 10; 4,5) 640  ms213R TGGCGTACTCCGAGCTGATG 
ms214 ms214F AAACGCTGTTCGCCAACCTCTA 
55 115 8(2-6; 12; 2,5; 5,5) 426  ms214R CCATCATCCTCCTACTGGGTT 
ms215 ms215F GACGAAACCCGTCGCGAACA 
55 129 8(1-7; 2,5) 765  ms215R CTGTACAACGCCGAGCCGTA 
ms216 ms216F ACTACTACGTCGAACACGCCA 
55 113 5(1-5) 543  ms216R GATCGAAGACAAGAACCTCG 
ms217 ms217F TTCTGGCTGTCGCGACTGAT 
55 109 8(1-6; 9; 1,5) 606  ms217R GAACAGCGTCTTTTCCTCGC 
ms222 ms222F AGAGGTGCTTAACGACGGAT 
55 101 9(1-7; 1,5; 5,5) 390  ms222R TGCAGTTCTGCGAGGAAGGCG 
ms223 ms223F TTGGCAATATGCCGGTTCGC 
55 106 7(2-7; 1,5) 454  ms223R TGAGCTGATCGCCTACTGG 
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2.2.4.2 Gel electrophoresis 
Gel electrophoresis was performed to determine the sizes of the VNTRs for each strain. 
Electrophoresis was performed on 20cm, 2% 1xTBE (89 mM Tris, 89 mM borate, 2.5mM 
Ethylenediaminetetraacetic acid gels. Amplicons were mixed with Novel Juice (GeneDireX) 
for DNA visualization at a ratio of 5:1 and run for 4 hours at 110 volts. The gels were 
visualised on the Alliance 2.7 (UViTec) optic analysis system. A 50bp DNA ladder (New 
England Biolabs) was used to determine the product sizes.  
2.2.4.3 MLVA genotyping 
The amplicon sizes were used to determine the allele sizes and to deduce the number of 
repeats at each locus, as described by Vu-thien et al., (2007)[34] and Youenou et al., 
(2014)[24] (Table 2.2). The bands were separated sufficiently for accurate size determination 
when compared to the DNA ladder and previously described allele sizes. The repeat number 
of the allele at each locus was combined in the order ms77, ms127, ms142, ms172, ms211, 
ms212, ms214, ms215, ms216, ms217, ms222, ms223, ms213 to create an MLVA pattern 
which was used to manually define an arbitrarily numbered MLVA type.  
MLVA data with arbitrarily numbered MLVA type information were added to the MLVA 
genotyping database MLVAbank for Microbes Genotyping (http://mlva.u-
psud.fr/mlvav4/genotyping/). Clustering of the MLVA types was analysed using MLVAbank 
to construct  a Newick dendrogram (Fredslund, 2006).[107]  
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Table 2.2: Thirteen VNTR loci allele band sizes[24]. Each VNTR locus contains a different 
number of tandem repeats which results in a different size allele. Red – PAO1 allele sizes 
and repeat numbers. Adapted from Vu-thien et al., (2007)[34] and Youenou et al., (2014).[24] 
VNTR 
locus 
Repeat 
size 
Number 
of 
repeats  
Allele 
size 
 
VNTR 
locus 
Repeat 
size 
Number of 
repeats 
Allele 
size 
 
VNTR 
locus 
Repeat 
size 
Number of 
repeats 
Allele 
size 
ms77 39 
1 325 
 
ms214 115 
2 311 
 
ms213 103 
0 125 
2 364 
 
3 426 
 
1 228 
3 403 
 
4 540 
 
2 331 
4 442 
 
5 655 
 
3 434 
5 481 
 
6 770 
 
4 537 
6 520 
 
12 1345 
 
5 640 
1.5 344 
 
2,5 368 
 
6 743 
2.5 384 
 
5.5 712 
 
7 846 
ms127 15 
8 210 
 
ms215 129 
1 378 
 
9 1052 
9 225 
 
2 507 
 
10 1155 
ms142 115 
1 201 
 
3 636 
 
4.5 588 
2 316 
 
4 765 
 
5.5 691 
3 431 
 
5 894 
  
 
  4 546 
 
6 1023 
  
 
  5 661 
 
7 1152 
  
 
  6 776 
 
2.5 571 
  
 
  7 890 
 
ms216 113 
1 315 
  
 
  12 1465 
 
2 428 
  
 
  2.5 373 
 
3 543 
  
 
  3.5 488 
 
4 656 
  
 
  
ms172 54 
8 627 
 
5 769 
  
 
  9 681 
 
ms217 109 
1 497 
  
 
  10 681 
 
2 606 
  
 
  11 735 
 
3 715 
  
 
  12 789 
 
4 824 
  
 
  13 843 
 
5 933 
  
 
  8.5 654 
 
6 1042 
  
 
  
ms211 101 
2 360 
 
9 1369 
  
 
  3 461 
 
1.5 551 
  
 
  4 562 
 
ms222 101 
1 289 
  
 
  5 663 
 
2 390 
  
 
  6 764 
 
3 491 
  
 
  7 865 
 
4 592 
  
 
  8 966 
 
5 693 
  
 
  9 1067 
 
6 794 
  
 
  1.5 310 
 
7 895 
  
 
  
ms212 40 
3 284 
 
1.5 339 
  
 
  4 324 
 
5.5 743 
  
 
  5 364 
 
ms223 106 
2 242 
  
 
  6 404 
 
3 348 
  
 
  7 444 
 
4 454 
  
 
  8 484 
 
5 560 
  
 
  9 522 
 
6 666 
  
 
  11 602 
 
7 772 
  
 
  12 642 
 
1.5 295 
  
 
  14 722 
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2.2.4.4 VNTR sequence analysis  
Amplicons which were of allele sizes that were not described in the literature were sent to 
Inqaba biotech™ for Sanger sequencing. The sequences were analysed using BioEdit 
Sequence Alignment Editor (Hall, 1999)[108] to determine the allele size and repeat number. 
Certain sequences were blasted using the NCBI (National Centre for Biotechnology 
Information) BLAST (Basic Local Alignment Search Tool) server 
(https://www.ncbi.nlm.nih.gov/) for the identification of insertion sequences.  
2.2.5 Ethics 
Ethical approval was obtained from the Health Research Ethics Committee of Stellenbosch 
University. Ethics reference: (S15/02/019) (A4 Appendix). 
2.3 Results 
2.3.1 Isolate collection 
A total of 80 P. aeruginosa isolates were typed using MLVA typing. Forty isolates were 
obtained from patients within the burns unit and the burns ICU. Samples were collected from 
a number of sites including CVC (central venous catheter) tips, wound/pus swabs, sputum, 
blood cultures and tissue. Another forty samples were isolated from patients hospitalized in 
wards other than the burns unit and burns ICU at Tygerberg Hospital. These included 
patients with pneumonia, sepsis, cystic fibrosis, abscesses and surgical site infections. The 
samples were categorised into three specimen types; Respiratory, Swab/tissue and 
Blood/Other specimens, and into three ward types; Paediatric, Surgery and Medical (Table 
2.3). Respiratory specimens included any samples from the respiratory tract such as 
aspirates, sputum and washings. Swabs and tissue specimens included pus, fluid and tissue 
biopsies from wounds. Blood and other specimens included blood cultures and CVC tips. 
Table 2.3: Specimen types and ward types of non-burn isolates. Ward information was 
not available for nine of the isolates. 
Specimen type No. of Samples Ward type, n 
Respiratory 12 
Paediatric, 2 
Surgery, 2 
Medical, 5 
Swab/Tissue 21 
Paediatric, 2 
Surgery, 13 
Medical, 2 
Blood/Other 7 
Paediatric, 0 
Surgery, 3 
Medical, 2 
Total 40 
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2.3.2 MLVA typing 
MLVA typing was done on the 80 P. aeruginosa isolates. The allele sizes and repeat 
numbers of 13 loci were determined for each isolate. For example, the allele sizes for all 13 
VNTR loci of control strain PAO1 are represented in figure 2.2. The allele repeat number of 
each locus was determined and then combined to form the MLVA type. The assigned MLVA 
pattern for PAO1 was 4,8,12,7,5,9,3,4,3,2,2,4,5. 
 
Figure 2.2: Gel electrophoresis of PAO1 with 13 VNTR loci.  M-Molecular marker (DNA 
ladder 1350bp), 1-13: VNTR loci ms77, ms127, ms172, ms142, ms211, ms212, ms214, 
ms215, ms216, ms217, ms222, ms223, ms213.  
 
Certain loci showed amplification of band sizes that are not described in the literature or 
could not be differentiated successfully from other alleles since the size differences were too 
small to be visualized with gel electrophoresis. Several amplicons appeared to be slightly 
bigger than other corresponding alleles on the gel and representative amplicons of these 
alleles were sent for sequencing to confirm the size of the alleles. Sequencing of ms172 
from TBP 36, ms212 from TBP 57 and ms217 from TBP 6 confirmed the previously 
described allele sizes (Appendix Table A1 and Table A2) of 843bp, 602bp and 497bp, 
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respectively, allowing the correct VNTR repeat numbers to be assigned (Table 2.4). The 
apparent difference in size that was seen on the gel may be due to the gel melting because 
of the long run and rising temperature, which resulted in the bands shifting slightly. This can 
be overcome by reducing the voltage and extending the run time to keep the buffer 
temperature low.  
Table 2.4: New and confirmed allele sizes and repeat numbers determined. N – Newly 
described allele sizes. C – Confirmed allele sizes. 
Locus (representative 
isolate sequenced) 
Size (bp) Allele repeat number 
ms172 (TBP 36) 843 13 (C) 
ms212 (TBP 57) 602 11 (C) 
ms217 (TBP 6) 497 1 (C) 
ms172 (TBP 33) 897 14 (N) 
ms212 (TBP 24) 147 0.5 (N) 
ms215 (TBP 3) 281 0.25 (N) 
ms215 (TBP 69) 66 None 
ms216 (TBP 69) 196 0 (N) 
ms223 (TBP 6) 205 1.125 (N) 
 
Previously undescribed allele sizes were obtained for a number of loci. The representative 
loci that were sequenced included ms172 from TBP 33, ms212 from TBP 24, ms215 from 
TBP 3 and TBP 69, ms216 from TBP 69, and ms223 from TBP 6 (Table 2.4). For TBP 3 a 
281bp product was obtained for locus ms215 which correlates with a repeat unit number of 
0.25 and was detected in 35 isolates. Other previously undescribed VNTR product sizes 
included an 897bp product for ms172 from TBP 33, a 66bp product for ms215 from TBP 69, 
a 147bp product for ms212 from 4 isolates, a 196bp product for ms216 from TBP 69 and a 
205bp product for ms223 from 2 isolates. A new allele number was assigned to each new 
allele size (Table 2.4). Studies have previously shown the presence of half repeat sizes;[24][34] 
for example, if a repeat size is 54bp (ms172) a repeat of 27bp was identified. Here we 
describe the presence of 0.25 and 0.125 repeat sizes.  
An allele repeat number could not be assigned to locus ms215 for isolate TBP 69 and 
numerous other loci also failed to amplify in this isolate (Appendix Table A2). 16S rRNA PCR 
and sequencing was performed on the isolate to confirm its identity and it was found to be 
Acinetobacter baumannii with 99% sequence homology with published sequences and 
therefore excluded from further analysis. Failed amplification, noted as NA (No amplification) 
in Table A1 and A2 (Appendix), also occurred for some loci in some other isolates. This 
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occurred more frequently in non-burn isolates than in burn isolates. Only four isolates from 
the burns unit/ICU had missing amplification at one locus; while five non-burn isolates failed 
to amplify between one and three loci.   
Two isolates, TBP 40 and TBP 46, produced products of 1300 – 1500bp for VNTR loci 
ms216 and ms223 respectively. This phenomenon is known to occur in P. aeruginosa MLVA 
typing and is a result of an insertion sequence present within the locus. The PCR amplicons 
were sequenced and the IS elements in both were identified as the IS110 family 
transposase.   
2.3.3 MLVA analysis (Burn and non-burn isolates) 
Isolates from patients in the burns unit and burns ICU were compared to each other as well 
as to non-burn patient isolates. MLVA analysis identified forty two different MLVA types 
amongst the 79 isolates (TBP 69 excluded) (Table 2.5). Ten of the MLVA types were shared 
by two or more isolates, while the remaining 32 types were represented by a single isolate 
and had unique MLVA patterns.  
Table 2.5. MLVA typing results of P. aeruginosa isolates from patients in the burns 
unit/ICU and non-burns wards at Tygerberg hospital. A total of thirteen VNTR loci were 
used to create an MLVA pattern for each isolate, which represents an MLVA type. Unique 
MLVA types represent MLVA patterns which were only identified in one isolate. 
MLVA type MLVA pattern  
Burns 
unit (n) 
Non-burns (n) Total 
1 3,9,13,1,3,9,4,0.25, 1,5,1,4,6 24 1 25 
2 3,9,13,1,7,0.5,4,0.25,1,5,1,4,6 4 0 4 
3 2.5,8,11,4,8,11,4,1,2,3,1,2,1 2 0 2 
4 2.5,8,12,2,3,8,5,6,1,4,1,2,4 0 2 2 
5 2,8,10,1,2,6,4,1,1,4,2,2,3 1 1 2 
6 4,9,13,1,3,9,4,0.25,1,5,1,5.5 3 0 3 
7 2,8,11,5,4,6,2,1,2,2,1.5,2,5 0 2 2 
8 2,8,11,4,8,11,4,1,2,3,1,2,1 0 3 3 
9 2,8,12,4,8,9,2,4,2,4,3,3,2 0 2 2 
10 3,9,13,1,3,3,4,0.25,1,5,1,4,6 0 2 2 
Unique Varying patterns 6 26 32 
Total  40 39 79 
 
MLVA types 1, 2, 3, 5 and 6 were identified in isolates from the burns unit/ICU. Sixty percent 
(24 /40) of the isolates from the burns units/ICU belonged to MLVA type 1. The second most 
abundant MLVA type, MLVA type 2, was identified in four isolates, while two MLVA type 3 
isolates and three MLVA type 6 isolates were identified. Six of the forty burns isolates had a 
unique pattern which did not correspond to any other isolate. MLVA types 1, 4, 5, 7, 8, 9 and 
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10 were identified amongst the non-burn isolates (Table 2.5). Only one of the non-burn 
isolates was MLVA type 1. One MLVA type, type 5, had isolates belonging to patients in the 
burns unit/ICU and outside of the burn unit. Two MLVA type 4 isolates were identified, both 
of which were from young patients (<7years) with cystic fibrosis. Twenty six of the non-burn 
isolates had unique MLVA types, and no more than three non-burn isolates clustered within 
an MLVA type. The results show that non-burn isolates are much more diverse than those 
from the burns unit and burns ICU.  
2.3.4 MLVA clustering analysis 
MLVA data was added to MLVAbank for Microbes Genotyping (http://bacterial-
genotyping.igmors.u-psud.fr/). A dendrogram was constructed to represent the clustering of 
the different MLVA types using 13 loci and 10 loci respectively, to determine how the number 
of loci analysed influences the assignment and clustering of MLVA types (Figures 2.3 and 
2.4). Clusters are seen localized on one branch. Some type 1 isolates, such as TBP 15 and 
TBP 26, failed amplification at locus ms214, and TBP 18 failed amplification at ms127. 
These loci were therefore excluded from the phylogenetic analysis.  
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Figure 2.3: Dendrogram showing MLVA type clustering using 13 VNTR loci. Red: Burn 
isolates, Green: Non-burn isolate, Blue: PAO1 control. 
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Figure 2.4: Dendrogram showing MLVA type clustering using 10 VNTR loci. Red: Burn 
isolates, Green: Non-burn isolate, Blue: PAO1 control. 
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The clustering of the MLVA Type 1 isolates is clear on the dendrograms when using 13 loci, 
as is the clustering of the other 9 MLVA types with more than one isolate. MLVA type 3 and 
MLVA type 8 cluster together, and differ with only one allele size difference at locus ms77. 
TBP 30 and TBP 53 (both unique MLVA types) also cluster together, and differ only at locus 
ms77.  Two non-burn isolates, TBP 5 and TBP 50 (classified as unique strains), also differ 
from each other with one allele repeat at locus ms77; and also differ from type 9 isolates 
only at locus ms77. Overall, locus ms77 appears to be responsible for most of the single 
differences that are found between MLVA types.  
When using only 10 loci (excluding ms77, ms127 and ms172), as previously used by Vu-
thien et al., (2007)[34] MLVA types 3 and 8 form one MLVA type; two additional isolates, TBP 
5 and TBP 50 which were unique types, are included in MLVA type 9; and TBP 30 and TBP 
53 are classified as the same MLVA type. The number of clusters remained the same but 
the number of unique MLVA patterns was reduced from 32 to 29. It appears that reducing 
the number of VNTR loci reduces the discrimination of MLVA typing considerably in this 
isolate collection compared to the study by Onteniente et al.,(2003)[20] which did not lose 
discrimination. This is most likely due to the fact that ms77 is excluded and appeared to be 
responsible for most of the differences between MLVA types in our population. 
2.4 Discussion  
This study investigated the population structure of P. aeruginosa isolates obtained from 
patients at Tygerberg Hospital, who were either admitted to the burns unit and burns ICU or 
the other wards within the hospital. P. aeruginosa is a major health problem in Tygerberg 
Hospital, especially in terms of nosocomial infections and particularly in the burns unit and 
burns unit ICU which accounted for 38% of isolates collected. A total of 80 isolates were 
typed using thirteen VNTR locus MLVA analysis. The pathogen P. aeruginosa has at least 
201 tandem repeats within its genome, of which several are VNTRs.[20] These VNTRs are 
polymorphic, meaning that there is more than one allele present within a population. Forty 
two different MLVA types were described of which ten were most abundant and were found 
in more than one isolate. There were twenty four type 1, four type 2, two type 3, two type 4, 
two type 5, three type 6, two type 7, three type 8, two type 9 and two type 10 isolates. The 
rest of the isolates (32/80) were all unique MLVA types from single patient isolates. Five 
different MLVA types with one or more isolates were described for burn isolates and seven 
different types with one or more isolates for non-burn isolates. MLVA type 5 included both a 
burn and non-burn isolate.  
Majority of the isolates belonged to MLVA type 1 (25/80), all of which were isolated from 
patients in the burns unit/ICU, except for one isolate. The same was seen for MLVA type 2, 
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the second most abundant type, of which the isolates were all obtained from patients in the 
burns unit/ICU. This is an indication that organisms are regularly being spread from patient 
to patient within the burns unit/ICU. Transmission could be due to non-sterile methods, 
environmental contamination or equipment being shared between patients causing patient to 
patient transmission. This information has been communicated to the infection prevention 
control unit (IPC) at Tygerberg Hospital to address the issue. The IPC is actively involved in 
protecting patients and staff members from spreading infectious diseases within the hospital 
setting. Outbreaks of infectious diseases can occur when proper infection prevention control 
methods are not in place and can cause major morbidity and mortality.  
None of the non-burn isolates that had the same MLVA type were isolated from patients 
within the same ward. Looking at non-burn isolates, the MLVA type clusters were very small 
compared to the burn isolates with a maximum of three isolates belonging to any MLVA 
type. This indicates that very little patient to patient transmission occurs within or between 
wards.  
Organisms with similar MLVA patterns which differ at a single locus may be genetically 
related or share a recent common ancestor. However, sequencing results have shown that 
diversity at a specific locus can be very high and that these alleles of the same size may 
have unique sequences.[20] According to Le Fleche et al.,(2002) MLVA does contain 
phylogenetic information which can be useful to determine the ancestral relationship of some 
organisms.[109] A single change in one locus can also imply that it is the same strain but a 
different variant. Locus ms77 was shown to vary the most in our study. Clustering MLVA 
types can be difficult since only one change or deletion in the MLVA pattern or at a specific 
locus can result in a big change in the structure of a dendrogram. This can result in a branch 
shift out of a cluster giving a different representation of the isolate. For more accurate strain 
identification MLVA typing can be confirmed with PFGE or a sequence-based typing method. 
In some isolates there were failed attempts at amplifying certain loci; which could be due to 
deletions, complete or partial absence of the locus or mispairing of the allele.[20][34] This has 
also been found in a study conducted by Onteniente at al.,(2003)[20] where they found that 
12% of their isolates failed amplification at one or more loci. The specific reason for these 
deletions and mispairing is still unclear. 
 
The amplification of some loci resulted in products greater than 1.3kb in size. According to 
Vu-Thien et al.,(2007)[34] this can be explained by an IS (insertion sequence) element. 
Insertion sequences have been identified in more than one locus; particularly ms216 and 
ms223, the same loci that showed the presence of IS elements in our study. The sequences 
of these products were aligned on the NCBI website and an IS110 insertion sequence was 
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identified.  IS elements are partial DNA sequences known as transposons with the ability to 
move from one place to another within the genome of the organism. Environmental stress 
can induce transposition causing mutant strains to emerge.[105][110] 
In our study, thirteen loci were used for typing the isolates. According to Onteniente et 
al.,(2003)[20] it is possible to reduce the number of loci for typing to eight loci without losing 
any discriminatory power in the assay. Vu-Thien et al.,(2007)[34] showed that reducing the 
number of VNTRs to ten, using ms142, ms211, ms212, ms213, ms214, ms215, ms216, 
ms217, ms222, and ms223, can yield a much easier and robust assay. When reducing the 
number of VNTR loci to ten in our study, we found that a few unique isolates appeared to 
join existing MLVA types; MLVA type 3 and 8 merged to form one type, MLVA type 9 
received two more unique MLVA type isolates and two unique MLVA type isolates, TBP 30 
and TBP 53, that were previously defined as very similar MLVA types, were defined as the 
same MLVA type. This indicates that using 10 loci in our setting lowers the discrimination of 
MLVA typing, compared to using 13 loci.   
 
Two loci, namely ms207 and ms209, were not included in the MLVA typing assay as 
difference in base pairs between the alleles are too small (6bp repeat unit) to discriminate by 
normal gel electrophoresis. Alternative methods such as sequencing, polyacrylamide gel 
electrophoresis or even capillary electrophoresis are required, which remain expensive and 
time consuming.[20][34] This is a limitation to our study since these loci have been shown to be 
the more polymorphic loci within the P. aeruginosa genome and to increase the 
discriminatory index of MLVA typing; however studies still tend to exclude these loci.[34]  
 
Studies have shown that the discriminatory power of MLVA is much higher than ribotyping 
as well as serotyping.[34][20] In a study by Onteniente et al.,(2003) when testing 89 isolates, 
MLVA discriminated 72 different genotypes while ribotyping and serotyping only 
discriminated 46 and 12 respectively.[20] MLVA was also shown to be much faster compared 
to the gold standard PFGE and can generate the same discrimination as PFGE when using 
up to only nine loci.[97] A study by Vu-thien et al.,(2007)[34] showed that including other 
organisms (not P. aeruginosa) in the MLVA assay using P. aeruginosa specific primer sets 
resulted in loci not amplifying or producing a faint band; whereas P. aeruginosa will produce 
a distinct solid band. In our study, one isolate had multiple loci which failed amplification and 
was confirmed not to be P. aeruginosa. This indicates that the assay has a high specificity 
for P. aeruginosa. 
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MLVA was shown to be a very robust molecular typing method for P. aeruginosa. This 
genotyping method could be enhanced by sequencing the products while combining 
fluorochromes and using loci which have different sizes for PCR. This would enable the 
genotyping of a single isolate with only one run.[34] The alternative, PFGE, which is the gold 
standard for strain typing, has been shown to be labour intensive and expensive. MLVA 
shows high inter laboratory reproducibility and discrimination and is relatively inexpensive 
but also remains somewhat labour intensive and time consuming for clinical strain typing. 
 
2.5 Conclusion  
The study of the population structure of P. aeruginosa at Tygerberg Hospital identified a 
number of clones within the burns unit and burns ICU, and specifically one MLVA type which 
accounted for 60% of P. aeruginosa infections in these wards; which is an indication of 
nosocomial transmission. There is more strain diversity found outside these wards. This 
could be explained due to less patient to patient transmission occurring within other wards 
compared to the burns/ICU ward. However this analysis is limited by our study design, as 
only 40 randomly selected isolates were selected from the entire Tygerberg Hospital, to span 
the collection period. Therefore it is not possible to rule out more transmission between 
patients outside of the burns unit/ICU. Focussing on just one ward and isolating all P. 
aeruginosa organisms from that specific ward may reveal different results.  There is a need 
for better infection prevention control in the burns unit and burns ICU and medical staff need 
to be informed and trained accordingly. Accurate typing methods such as MLVA need to be 
implemented to understand the epidemiology of the organism for early identification of 
outbreaks and rapid treatment to prevent further transmission. MLVA is easy to perform 
withhigh discriminatory power and reproducibility and was shown to be a promising method 
for future strain typing and outbreak investigations in P. aeruginosa. 
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Chapter 3 
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Chapter 3 – Biofilm analysis 
3.1 Introduction 
Biofilms consist of cells attached to a surface and also to each other, surrounded by an 
extra-polymeric substance which helps the organism by providing protection against 
antibiotic agents and biocides by preventing them from diffusing into the biofilm and also 
protects against the host’s immune system.[111] P. aeruginosa is renowned for developing 
multidrug resistance and persistent chronic infections due to biofilm formation.[48] Biofilms 
commonly occur on medical devices, open wounds and respiratory tracts. The prevention of 
spread and treatment of persistent infections become more difficult due to biofilm formation 
and multidrug resistance.  
Several studies have shown that P. aeruginosa is linked to burn wound infections causing 
high mortality rates and that P. aeruginosa is one of the most frequent organisms isolated 
from this setting.[8][7] These isolates are also potential biofilm formers and often result in 
biofilm related sepsis.[112] Patients with severe burn wounds stand a higher chance of 
developing an infection due to the destruction of the skin’s natural defence barrier and other 
defences.[112] Sepsis among patients in burn ICUs has also been reported to be caused by 
P. aeruginosa in up to 14-20% of cases.[4] Burn wounds may be free of any infective 
organisms but are prone to infections due to organisms within sweat glands and hair follicles 
that are able to colonize the wound. 
There are several different ways in which biofilms can be quantified. Different methods such 
as the Syto9, FDA, resazurin, XTT and dimethylmethylene blue assay are commonly used 
but can be expensive and time consuming. In this study biofilm assays were performed 
using crystal violet staining in 96 well micro titre plates, which is a commonly used method 
due to the reproducibility, time efficiency and the low cost involved. The aim of this study 
was to determine the biofilm formation ability of isolates from the burns ward/ICU and 
outside the burns ward at Tygerberg hospital. The biofilm forming ability of isolates from 
patients with burn wounds and isolates from non-burn associated infections were compared 
and differences in the capacity of different strain lineages, as identified by MLVA typing, to 
form biofilms was also assessed. 
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3.2 Materials and methods 
3.2.1 Isolate selection 
The clinical isolates described in Chapter 2 were used in the biofilm assays. A control strain, 
PAO1 Harvard (obtained from the National Institute of Communicable Diseases (NICD)) was 
included in all biofilm assays since it is a known biofilm former.[112]  
3.2.2 Biofilm time-point assay  
Biofilm analysis was done using the micro titre plate method, as previously described by 
O’Toole (2011)[113]. Glass broth bottles containing 10 ml TSB (Tryptic Soy Broth, Sigma), that 
contains sufficient glucose for cell growth, were inoculated with a microbank bead of the 
relevant isolate and incubated for 24 hours at 37˚C, with continuous shaking at 180 rpm, in a 
Labcon O2 shaker incubator (Lasec). A 1:200 dilution of the overnight growth was made in 
fresh TSB media in a 1.5ml Eppendorf tube and vortexed for 5 seconds to ensure even 
suspension.  
A micro titre flat well plate (Corning Costar Cell culture plates, 3595) (tissue culture treated 
for easy cell attachment) was inoculated with 200µl of the diluted cell suspension. Plates 
were incubated for varying durations (2h, 5h, 8h, 10h or 12h) at 37˚C, without shaking. After 
incubation, the wells were washed 3 times with millipore dH2O to remove any loose cells. 
Any biofilm formed would be left behind in the well, and was heat fixed for 1 hour at 60˚C on 
a heating block (Accublock, Labnet).  The wells were then treated with 200µl of 0.1 % crystal 
violet (Sigma) for 10 minutes to stain the formed biofilm. The plate was washed 3 times with 
dH2O to remove the excess stain and air dried at 37˚C. Finally, 200 µl of 30% acetic acid 
was added to the wells and left for 10 minutes to dissolve the crystal violet stain to enable 
consistent absorbance measurements. The absorbance values of the wells were read in a 
micro titre plate reader (Biotek, Synergy HT) at 595nm. Higher absorbance values indicate 
more biofilm material in the well, and thus a ‘stronger’ biofilm forming organism.  
The assay was performed in both biological and technical triplicate. Biological replicates 
were done using inoculations of three different microbank beads to control for biological 
variation between different samples of the organism. Technical replicates were done by 
inoculating three wells with the same inoculation which controls for human error. These 
replicates are necessary to determine the reproducibility of the assays. Average absorbance 
values and standard deviations were calculated for each time point. 
Initial optimisation of the assay, using the 5 different incubation times described above, was 
performed on a convenience sample of 12 of the clinical isolates (TBP 24-36) as well as the 
control strain, PAO1. These thirteen isolates were selected to determine the optimal 
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incubation time for biofilm formation. Based on the optimisation assay, the biofilm formation 
of all 79 isolates (excluding TBP 69 - non burns) was tested using the above methodology 
after incubation of the plates for 12 hours.   
3.3 Results 
3.3.1 Optimisation of the biofilm formation time-point assay 
Thirteen isolates were selected to perform a time point assay to select an ideal incubation 
time to assess biofilm formation. These isolates included TBP 24-35 which were isolated 
from patients in the burns unit/ICU and TBP 36 from a different ward (Figure 3.1).  
Three distinct biofilm formation patterns were observed, as shown in Figure 3.1. Most 
isolates showed some increase in biofilm formation over time; this pattern of increasing 
biofilm could be classified in three categories characterised by a small, moderate or rapid 
increase. Isolates TBP 25 and TBP 26 showed a small increase in biofilm formation, with a 
maximum absorbance of <0.25 after 12 hours; the majority of the isolates showed a 
moderate increase in biofilm formation with increasing incubation time (TBP 24, 27, 28, 29, 
30 and 33); while TBP 34 showed a rapid increase over time, with an increase in 
absorbance of more than a 0.5 between each time point. The second pattern, observed in 
TBP 32 shows no noticeable increase over time.  The third pattern showed a rapid increase 
in biofilm formation in the first 2-5h followed by a decrease in biofilm formation which may 
indicate that the biofilm was starting to disperse (TBP 31 and PAO1). Isolates TBP35 and 36 
showed a similar increase over the first 8 -10h and appeared to be either on the verge of 
dispersing or increasing by 12h. 
The results of the optimisation showed that measuring biofilm formation at either 10 or 12 
hours would reliably differentiate between different biofilm forming abilities, although one 
would not be able to differentiate between isolates that have ongoing biofilm formation 
compared to those which may be dispersing after 5 hours (e.g. TBP 31 and PA01). 
Therefore, given the technical challenges associated with performing biofilm assays on all 79 
isolates at multiple time points, we elected to perform the assay on the collection of 79 
isolates at a single time point at 12 hours. 
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Figure 3.1: Biofilm formation time point assay. Biofilm formation was measured at 5 time points over 12 hours (2, 5, 8, 10, 12h). 13 isolates (TBP 24-36) 
were analysed and three distinct formation patterns described; increase in biofilm formation, no noticeable increase in biofilm formation and increase 
followed by dispersal. Absorbance values were measured at 595nm. P – Control strain (PAO1) 
Moderate increase. 
Rapid increase. 
Small increase 
Increase followed 
by dispersal. 
Moderate increase. 
No increase. 
Moderate increase. 
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3.3.2 Biofilm formation of isolates from different clinical settings 
Based on the results of the time point assay further biofilm analysis was carried out on all 79 
isolates after a 12 hour stationary incubation. The control strain PAO1 is a moderate biofilm 
former according to our study and formed biofilms with an average absorbance value which 
ranges from 0.25 to 0.5. Based on this, for the purposes of this study, we defined strong 
biofilm formers as having an absorbance of more than 0.5, moderate biofilm formers as 
having an absorbance of 0.25-0.5 and weak to non-biofilm formers as having an absorbance 
value of less than 0.25 at an incubation time of 12 hours. 
For both the isolates from patients in the burns unit and from other patients, there was a 
wide range of biofilm formation (Figure 3.2 and 3.3). There was more variation in biofilm 
forming ability among burns unit/ICU isolates than in non-burn isolates. Amongst the burn 
isolates, 55% (22 out of 40) were strong biofilm formers with the strongest biofilm former 
showing an absorbance of 3.64 (Table 3.1), 40% of the isolates (16 out of 40) showed weak 
to no biofilm formation, while only 5% (2 out of 40) were moderate biofilm formers. The 
majority of the non-burn isolates, 72% (28 out of 39), are strong biofilm formers; with the 
strongest biofilm former reaching an absorbance value of 1.63. Only 13% (5 out of 39) of the 
isolates showed weak to no biofilm formation (Table 3.1). Overall, strong biofilm formers 
were more common amongst non-burn isolates. 
Table 3.1: Biofilm forming abilities of isolates from the burns unit/ICU compared to isolates 
collected from outside the burns unit. 
Biofilm formation categories Burns unit/ICU:  n, (%) Other wards: n, (%) 
Weak biofilm (<0,25) 16, (40%) 5, (13%) 
Moderate biofilm (0,25 – 0,5) 2, (5%) 6, (15%) 
Strong biofilm (>0,5) 22, (55%) 28, (72%) 
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Figure 3.2: Biofilm formation 12h assay. Biofilm formation of 40 isolates from the burns unit and burns ICU after an incubation time of 12 hours. 
Absorbance values were measured at 595nm. PAO1 – Control strain. Orange: Strong biofilm former (>0.5), Blue: Moderate biofilm former (0.25-0.5), Green: 
Weak biofilm former (<0.25). 
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Figure 3.3: Biofilm formation 12h assay. Biofilm formation of 39 non-burn isolates after an incubation time of 12 hours. Absorbance values were measured 
at 595nm. PAO1 – Control strain. Orange: Strong biofilm former (>0.5), Blue: Moderate biofilm former (0.25-0.5), Green: Weak biofilm former (<0.25). 
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3.3.3. Biofilm formation of isolates based on specimen type 
The biofilm forming ability of isolates was further analysed based on the specimen type. 
Isolates were obtained from several sample types and categorised in four categories, 
wound/pus swabs and tissue, CVC (central venous catheter) tips, blood cultures and 
sputum. One isolate’s data was not indicated on the patient information form. The biofilm 
forming ability of isolates from each specimen type from both the burns unit/ICU and outside 
the burns unit/ICU was determined (Tables 3.2 and 3.3 respectively). The majority of the 
burns unit/ICU isolates were obtained from wound/pus swabs and tissue (26 out of 40). 
Isolates from wounds/pus swabs, tissue and blood cultures had a range of strong, moderate 
and weak biofilm formation abilities. The majority of the isolates from CVC tips (67%) 
appeared to be weak biofilm formers. 
Table 3.2: The biofilm formation ability of burns unit/ICU isolates classified according to 
specimen type.  
Specimen type 
Strong: n, 
(%) 
Moderate: n, 
(%) 
Weak: n, 
(%) 
Wound/pus swabs/tissue (n=26) 16, (61.5%) 2, (7.7%) 8, (30.8%) 
CVC tips (n=6) 2, (33%) 0 4, (67%) 
Blood cultures (n=6) 3, (50%) 0 3, (50%) 
Sputum (n=2) 0 0 2, (100%) 
 
There were more isolates that form strong biofilms amongst the non-burn isolates. The 
majority of the isolates from wounds/pus swabs/tissue, CVC tips and sputum were strong 
biofilm formers (67%) (Table 3.3). Very few isolates appear to be weak biofilm formers; 
accounting for 33% of blood culture, 18% sputum isolates and 5% of wound isolates, but 
only 12.8% of isolates overall. 
Table 3.3: The biofilm formation ability of non-burns unit isolates classified according to 
specimen type.  
Specimen type 
Strong: n, 
(%) 
Moderate: n, 
(%) 
Weak: n, 
(%) 
Wound/pus swabs/tissue (n=21) 17, (81%) 3, (14%) 1, (5%) 
CVC tips (n=1) 1, (100%) 0 0 
Blood cultures (n=6) 2, (33%) 2, (33%) 2, (33%) 
Sputum (n=11) 8, (73%) 1, (9%) 2, (18%) 
 
We compared the burn unit/ICU specimen types to those of the non-burn specimen types. It 
appeared that the majority of the wound isolates from both the burns unit (61.5%) and non-
burns units (81%) were strong biofilm formers. More isolates from the burns unit/ICU had a 
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lower biofilm forming capability as shown by high proportions of isolates from CVC tips 
(67%), blood cultures (50%), and sputum (100%) which formed weak biofilms.  
When analysing the biofilm formation ability of all isolates, independent of the ward of origin, 
it is clear that the wound/pus swabs and tissue specimens were the most common 
specimens and these isolates were predominantly strong biofilm formers (Table 3.4). The 
majority of sputum isolates were also strong biofilm formers, while similar proportions of 
isolates from CVC tips and blood cultures were strong and weak biofilm formers. 
Table 3.4: The biofilm formation ability of burns unit/ICU and non-burns unit isolates 
classified according to specimen type. 
Specimen type 
Strong: n, 
(%) 
Moderate: n, 
(%) 
Weak: n, 
(%) 
Wound/pus swabs/tissue (n=47) 33, (70%) 5, (11%) 9, (19%) 
CVC tips (n=7) 3, (43%) 0 4, (57%) 
Blood cultures (n=12) 5, (42%) 2, (16%) 5, (42%) 
Sputum (n=13) 9, (67%) 1, (8%) 3, (25%) 
 
3.3.4 Biofilm formation based on strain type  
Chapter 2 described the population structure of the isolates based on MLVA typing. The 
biofilm forming ability of the most abundant MLVA types (Types 1-10) were compared (Table 
3.5, Figures 3.4 and 3.5). Isolates belonging to unique MLVA types were not included. The 
most predominant MLVA type was type 1 which included 25 isolates of which 24 were 
isolates from patients within the burns unit/ICU. Different isolates from MLVA type 1 showed 
different levels of biofilm formation (Figure 3.4). As seen in Table 3.5, 56% (14 / 25) of the 
type 1 isolates showed weak to no biofilm forming ability while 40% (10 / 25) showed strong 
biofilm forming ability.  
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Table 3.5: Biofilm forming abilities of different MLVA types 
MLVA type 
Clinical 
ward 
Strong: n, (%) 
Moderate: n, 
(%) 
Weak: n, (%) 
1 (n=25) Burns/non-
burn 
10, (40%) 1, (4%) 14, (56%) 
2 (n=4) Burns 2, (50%) 1, (25%) 1, (25%) 
3 (n=2) Burns 0 0 2, (100%) 
4 (n=2) Non-burn 2, (100%) 0 0 
5 (n=2) Burns/Non-
burn 
2, (100%) 0 0 
6 (n=3) Burns 3, (100%) 0 0 
7 (n=2) Non-burn 2, (100%) 0 0 
8 (n=3) Non-burn 1, (33%) 1, (33%) 1, (33%) 
9 (n=2) Non-burn 2, (100%) 0 0 
10 (n=2) Non-burn 2, (100%) 0 0 
 
This lack of consistency in biofilm forming ability was also evident in isolates from MLVA 
types 2 and 8 (Figure 3.5). Biofilm formation varied from weak biofilm formation to strong 
biofilm formation. Isolates from MLVA types 3-10 (excluding type 8) showed more similar 
biofilm formation within each MLVA type, however the numbers of isolates in each MLVA 
type were small. The two MLVA type 4 isolates appear to have the most similar biofilm 
formation ability with a difference in absorbance of only 0.02. Within the other MLVA types, 
the isolates had differences in absorbance values ranging from 0.10 to 0.20. All MLVA types 
contained strong biofilm formers except for MLVA type 3, which were all weak biofilm 
formers. These results suggest that the genetic background of the isolates, as determined by 
MLVA, does not predict the ability of the isolate to form a biofilm. 
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Figure 3.4: Biofilm formation of MLVA type 1 isolates. Biofilm formation was measured at an incubation time of 12 hours. All of the isolates were burn 
patient isolates except for TBP 36. Absorbance values were measured at 595nm. Orange: Strong biofilm former (>0.5), Blue: Moderate biofilm former (0.25-
0.5), Green: Weak biofilm former (<0.25). PAO1 – Control strain.  
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Figure 3.5: Biofilm formation of MLVA type 2-10 isolates. Biofilm formation was measured at an incubation time of 12 hours. PAO1 – Control strain. 
Absorbance values were measured at 595nm. 
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3.4 Discussion 
This component of the study describes the biofilm forming ability of P. aeruginosa isolates 
from the burns ward/ICU and other wards at Tygerberg hospital, and compares the biofilm 
forming ability of isolates from different specimen types and MLVA types.  
A time point assay with 2h, 5h, 8h, 10h, and 12h incubation times was performed on a 
subset of isolates to determine the optimal incubation time to assess biofilm formation and to 
determine the reproducibility of the assay. A 12 hour incubation period was selected since 
this time point differentiated strong from weak biofilm forming isolates.  A decrease in biofilm 
formation was observed in some isolates after 8 hours, which could be an indication of the 
biofilm maturing resulting in the  dispersion of planktonic cells, aided by proteins breaking 
down the extra polysaccharide matrix.[84] This enables the organism to form a new biofilm at 
other sites once the environment is suitable.  
Biofilm assays were performed on all isolates at an incubation time of 12 hours. Forty 
percent of burns isolates were weak biofilm formers compared to only 13% of non-burns 
isolates; while the majority of non-burns isolates (72%) were strong biofilm formers 
compared to 55% of burns isolates.  P. aeruginosa and other biofilm forming organisms such 
as Staphylococcus epidermidis, Staphylococcus aureus and Escherichia coli are commonly 
isolated from burn wound related infections, however biofilm formation has not yet been 
described in burn wounds[111] 
Specimen type appeared to play a role in the biofilm forming abilities of the isolates. The 
majority of the isolates were from wounds, pus swabs and tissue and had strong biofilm 
forming abilities. Most sputum isolates were also strong biofilm formers, in contrast to blood 
culture and CVC tip isolates which were evenly distributed between strong and weak biofilm 
formation. Surprisingly, most isolates from CVC tips (particularly those from the burns 
unit/ICU) had weak biofilm forming ability. One would expect an organism from a prosthetic 
device to be a strong biofilm former since biofilms are known to grow on prosthetic devices 
such as orthopaedic implants, cardiac pacemakers and CVC tips.[111][114] The significance of 
these findings warrants further investigation, as the numbers of some specimen types were 
small. 
The biofilm formation ability of different P. aeruginosa strains, as determined by MLVA 
analysis, was compared. Considerable variation in biofilm formation ability was observed 
between isolates within a MLVA type, however with the exception of a few outliers, there 
was no obvious difference between the different MLVA types. More variation was observed 
within MLVA type 1 which is likely due to the large number of isolates belonging to this type. 
The least variation in biofilm formation was observed within MLVA type 4, which are all non-
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burns isolates. It is known that isolates within the same clone can be phenotypically diverse 
when forming biofilms, which could explain this phenomenon.[115][116] A study from Comeau et 
al.,(2001) has shown that organisms within a biofilm can undergo phase variation and exhibit 
different phenotypic traits and can switch between these phenotypes, which can affect 
biofilm formation.[117]  Different regulator proteins are active at different stages of the biofilm 
cycle and have been speculated to have the biggest impact on biofilm variation. The GGDEF 
and EAL protein domains in these regulators regulate the signal molecule c-di-GMP affect 
bacterial adhesion and aggregation.[115] Phenotypic variants which have the ability to form 
stronger biofilms when there is a sudden environmental change have previously been 
isolated. It is speculated that these organisms possess numerous mechanisms, including 
phase variation, adaptive mutation and gene transfer, which result in reversible phenotypic 
changes.[115][118] During the irreversible attachment stage it appears that physical properties, 
such as motility, can change. The Las and Rhl quorum sensing systems start playing a role 
during the attachment stage and maturing stage respectively, resulting in upregulation of a 
numerous genes which can all have an effect on the formation of a biofilm.[119] It is also 
possible that MLVA typing does not provide sufficient discrimination amongst these isolates 
and that further proteomic studies or whole genome sequencing may help to identify 
additional phenotypic and genotypic variation between isolates. 
A limitation of the study was that large standard deviations were observed between the 
biological triplicates of the biofilm assays. It is not clear why the same isolate would form 
biofilms of different strengths. It could be due to the organisms behaving differently due to 
small changes in the environment and/or cells undergoing physiological, metabolic and 
phenotypic changes. Variation due to technical factors can also be a factor. It has been 
shown that the reproducibility of biofilm formation readings in P. aeruginosa strains PAO1 
and ATCC 9027 using crystal violet staining was poorer than for other organisms such as 
Staphylococcus aureus, Propionibacterium acnes and Candida albicans and varied much 
more between experiments.[112] This can be explained by P. aeruginosa having more water 
in the extra cellular matrix of the biofilms which makes it difficult for the biofilms to attach to 
the plate properly.[112] This may also explain the change in biofilm formation that occurs after 
10-12h incubation when some of the isolates biofilms seem to weaken resulting in lower 
absorbance being measured. It is speculated that this is due to high water content of the 
polysaccharide matrix which P. aeruginosa is known for.[112]  
A study focussing on the formation of biofilms and the quantification thereof has shown 
similar results of the same or similar strains showing totally different biofilm formation ability, 
not only in P. aeruginosa but also in other organisms such as C. albicans.[116] A study from 
Sauer et al.,(2002) found that the protein activity of cells within a biofilm at different stages of 
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development may differ significantly resulting in biofilm changes.[119] P. aeruginosa in 
particular undergoes five different physiologies throughout the different stages of biofilm 
development, which means that cells within a different stage of biofilm development will be 
physiologically different from other cells. The different stages include reversible attachment 
and irreversible attachment where more than 11 proteins are shown to be active; and 
maturation 1, maturation 2 and finally dispersion of the cells back to planktonic cells.[119] 
Another study revealed that Pseudomonas putida shows a change in gene expression and 
the products thereof within the first 6 hours of biofilm formation.[120] These factors can vary 
between strains and have an effect on the outcome of biofilm formation. 
This study used a crude biofilm assay using crystal violet staining of the attached cells. 
Crystal violet staining and the concentration used has an impact on the biofilm formation 
measurements. A previous study using crystal violet showed that variation occurred within 
experiments as well as between experiments (technical and biological replicates).[112] Our 
biofilm formation assays showed lower absorbance measurements for PAO1 than were 
described by another study which used 0.5% crystal violet compared to our 0.1% crystal 
violet staining. Our crystal violet concentration was selected based on a method from O’toole 
(2011).[113] On the other hand, another study compared 0.1% crystal violet staining to 1.0% 
and found that higher variance was found with higher concentrations of crystal violet 
although there was no statistical difference in the biofilm measurement.[121] Crystal violet also 
only stains bacterial cells present in the well and not the extracellular polymer matrix and 
therefore an alternative should be used when this needs to be visualized.[122] Staining 
materials such as alcian blue, safranin or trypan blue can be used as alternative for staining 
the slimy layers. Another limitation of in vitro staining is that when staining biofilm formation 
of weak biofilm formers it tends to produce more false negatives compared to staining strong 
biofilm formers.[123] Crystal violet staining may not be the most effective method for the 
measurement of biofilm formation in P. aeruginosa since it can cause variability in the 
results. Alternative methods for biofilm quantification using 96 well micro titre plates can be 
implemented for more accurate and reproducible results. These include Syto9 assay, FDA 
assay (fluorescein diacetate), resazurin assay, XTT assay and dimethyl methylene blue 
assay. The crystal violet biofilm assay is a cheap and easy method for our setting compared 
to methods such as XTT and Syto9 assays which are laborious and also relatively 
expensive. Other more complex and more expensive methods which are not always 
available in the clinical environment include scanning electron microscopy, transmission 
electron microscopy, confocal laser microscopy and detecting genes that are present during 
biofilm formation. 
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Another observation that was made in our study was that the majority of the biofilm formed 
by some strong biofilm formers occurred at the top sides of the well, which was where most 
of the staining could be visualized before the stain was redissolved. This phenomenon was 
also observed in a study from Bendouah et al.,(2006) who performed biofilm forming assays 
of P. aeruginosa isolates isolated from patients with chronic sinusitis. This is expected since 
P. aeruginosa is an aerobic organism and also forms air-liquid interface biofilms.[123]  
Another factor that plays a significant role in biofilm formation is the growth medium being 
used. TSB, which was used in this study, is recommended for these types of assays since it 
contains enough glucose for growth.[122] An alternative growth medium that can be used is 
BHI medium (Brain heart infusion) but may affect biofilm formation differently. There are 
other important factors which can also influence biofilm formation and contribute to variable 
biofilm formation results. These include the amount of washing steps being performed on the 
plate. According to Stepanovic et al.,(2007)[122] three to four washing steps are sufficient; and 
three were used in our study. Using the correct micro titre plate for biofilm growth is also 
important. It is necessary to use a plate that has been treated for tissue culture to make it 
possible for the biofilm to attach to the surface. When reading the absorbance of biofilm 
formation the stained plates first need to be resolubilized in acetic acid or alternatives such 
as ethanol or methanol which will yield the same results. In this study 30% acetic acid was 
used. Resolubilizing the stained wells also aids in the equal distribution of the stained cells 
which is necessary since the micro titre plate reader only reads the absorbance in the middle 
of the well. These were all aspects that were taken into consideration in this study. 
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3.5 Conclusion 
Very little similarity was found between the biofilm formation of isolates from the same MLVA 
type, between the two different environments, namely the burns unit/ICU and non-burn 
wards, or between the different specimen types. Variation in the degree of biofilm forming 
ability was observed within the same MLVA types especially for the most abundant MLVA 
type 1. 
Based on published evidence it is clear that biofilm formation of organisms is a developing 
problem occurring in the clinical setting. Knowing the biofilm characteristics of P. aeruginosa 
can enhance the effectiveness of treatment of chronic persisting infections and may lift the 
burden of mortality, especially in burn wards where transmission occurs on a regular basis. It 
is suspected that organisms, especially P. aeruginosa, that are isolated from burn units are 
often biofilm formers. Although biofilm formation has not yet been described in burn patient 
wounds, it is known that biofilm related wound sepsis does occur, and biofilm formation has 
been described in mouse model burn wounds.[111] Biofilm formation is more frequently seen 
in chronic wounds than acute wounds, which is expected since chronic wound infections 
persist for longer. 
P. aeruginosa can be used as a model organism for describing biofilm formation in vitro as 
well as in vivo. Further studies can determine the susceptibility of biofilms to antibiotics and 
the formation thereof in the presence of antibiotics, as well as determining the factors that 
are responsible for biofilm variation of isolates from the same strain. Studies focussing on 
protein activity at different stages of the biofilm cycle can also be of value. 
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Chapter 4 
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Chapter 4 – Effects of antibiotics on biofilm formation 
4.1 Introduction 
Antibiotics work in different ways to inhibit growth or kill bacteria, and five different 
mechanisms of action have been described.[124] The most common mechanism, linked to 
penicillins, carbapenems and cephalosporins, is inhibiting cell wall synthesis by either 
breaking down peptidoglycan bonds or by inhibiting the formation of peptidoglycan. 
Secondly, antimicrobials may inhibit protein synthesis necessary for basic cell function by 
either affecting the function of ribosomes or tRNA, thus inhibiting translation. Antibiotics with 
this mechanism include aminoglycosides, tetracyclines and macrolides. The third 
mechanism, exhibited by lipopeptides such as daptomycin, affects the outer membrane and 
disrupts the cytoplasmic membranes. The fourth mechanism inhibits the formation of nucleic 
acids which are crucial for cell division and growth, by acting on enzymes such as DNA 
gyrase and topoisomerase, and includes antibiotics such as fluoroquinolones. Finally some 
antimicrobials, such as trimethoprim-sulfamethoxazole, have antimetabolite activity which 
inhibits the production of folic acid which is necessary for cell growth.[124]  
It has been established that in P. aeruginosa the biofilm will cause the movement of 
antibiotics, especially aminoglycosides, into the biofilm to be retarded.[47] This is however 
restricted by the limited receptors for inhibiting antimicrobial diffusion in the EPS. Another 
factor contributing to antibiotic resistance within biofilms is multidrug efflux pumps which are 
speculated to be upregulated in a  biofilm.[125] 
It is important to establish and understand the effect of antibiotics on biofilm formation for 
future treatment and prevention of biofilm associated infections. In this study we aim to 
describe the effect of different concentrations of antibiotics on the formation of P. aeruginosa 
biofilms. Four different antibiotics were tested on a subset of isolates and the impact on 
biofilm formation measured after various time periods to investigate their effect at different 
stages of biofilm formation. 
Four different antibiotics were chosen to represent different classes and mechanisms of 
action. The selected antibiotics are commonly used to treat P. aeruginosa infections.  One 
antibiotic each from the cephalosporin, quinolone, carbapenem and aminoglycoside groups 
were selected. Cefepime is a 4th generation cephalosporin which is active against both Gram 
positive and Gram negative bacteria, and acts by binding to the penicillin binding proteins 
which will disrupt cell wall synthesis. Ciprofloxacin belongs to the fluoroquinoloneclass of 
Stellenbosch University  https://scholar.sun.ac.za
   
60 
 
antibiotics and inhibits DNA replication by binding to DNA gyrase, which is responsible for 
the “supercoiling” of DNA. Imipenem is a carbapenem which also targets the penicillin 
binding proteins to disrupt cell wall synthesis. The fourth antibiotic, gentamicin belongs to the 
aminoglycoside group. Gentamicin binds to 16S ribosomal RNA within the 30S ribosomal 
subunit, close to tRNA, which affects the process of protein synthesis by inhibiting 
translocation of the ribosome.[124][126] In particular, we wanted to further investigate the effect 
of strain lineage on the effect of antibiotics on biofilm formation, and we also aimed to 
determine whether strong and weak biofilm forming organisms (as in Chapter 3) were 
affected differently by antibiotics. A better understanding of the effect of specific antibiotics 
on P. aeruginosa biofilm formation may help to advise future treatment and reduce the 
burden of morbidity and mortality it causes.  
4.2 Materials and methods 
4.2.1 Isolate selection 
A subset of isolates was selected to test the effect of antibiotics on biofilm formation. Five 
isolates were selected from three MLVA types according to their level/strength of biofilm 
formation. Two isolates (with strong or weak biofilm forming ability; section 3.3.4 were 
selected from each of the two most common MLVA types (types 1 and 2; section 2.3.2). The 
selected isolates included TBP 47 & 20 (MLVA type 1), TBP 16 & 23 (MLVA type 2) and 
TBP 73 (MLVA type 9) was included as a sensitive strain representative. A control strain (P. 
aeruginosa PAO1) was included in the assay as this strain is a known biofilm former.[112] The 
PAO1 and TBP 73 strains were included to represent sensitive strains as they are 
susceptible to all antibiotics used in the assay. 
4.2.2 MIC determination (Minimum inhibitory concentration) 
Isolates were tested for susceptibility to cefepime, imipenem, ciprofloxacin and gentamicin 
by determining the minimum inhibitory concentration (MIC) for each antibiotic using gradient 
diffusion (Etest strips, Biomerieux). Etest strips release a concentration gradient of 
antibiotics onto the agar and allow the MIC to be read at the point where the elliptical growth 
intersects the strip (Figure 4.1).  
Figure 4.1: Etest strip representation of elliptical growth 
intersecting with the strip at 0.75μg/ml. Source: Nasir et 
al., (2015)[127].  
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Each isolate was grown on TBA (tryptose blood agar, NHLS Greenpoint Media Laboratory) 
overnight at 37°C, where after single colonies were suspended in 2 ml of saline. The 
suspension was made up to a cell density of 0.5 McFarland as measured with a 
nephelometer (DensiCHEK plus, Biomerieux). The suspension was carefully spread on MH 
agar plates (Mueller Hinton, NHLS Greenpoint Media Laboratory) with a sterile cotton swab, 
covering the entire surface of the plate. Two Etest strips were used per plate, placed parallel 
to each other in reverse orientation on each half of the plate. The MH plates were incubated 
for 20h at 37˚C. The inhibition of growth of the organism was visualized on the plate and the 
MIC’s were interpreted and noted in μg/ml. The raw (uncorrected) MIC data were used to 
determine the antibiotic concentrations used in the biofilm assays. 
4.2.3 Antibiotic dilutions 
The following antibiotics and solutions were used: cefepime dihydrochloride monohydrate 
(40mg/ml, European pharmacopoeia), ciprofloxacin hydrochloride (30mg/ml, European 
pharmacopoeia), imipenem monohydrate (10mg/ml, Sigma) and gentamicin sulphate 
(50mg/ml, Sigma). Stock solutions and dilutions were made according to each antibiotic’s 
solubility and stored at -20˚C. Stock solutions for each antibiotic were made up as follows.  
 Cefepime: 32mg/ml dissolved in H2O  
 Ciprofloxacin: 16mg/ml dissolved in HCl  
 Imipenem: 5mg/ml dissolved in H2O  
 Gentamicin: 25.6mg/ml dissolved in H2O  
4.2.4 Biofilm assays. 
Biofilm assays were performed as described in Chapter 3, section 3.2.2, with the addition of 
antibiotics. Each isolate was tested with concentrations of each of the 4 antibiotics that 
corresponded to 10%, 50% and 100% of the MIC that had been determined by Etest for 
each isolate. Biofilm formation was measured at 4, 10 and 24 hours. Replicate plates were 
prepared for each time point.  
Antibiotic stock solutions were diluted in TSB (tryptic soy broth, Sigma) in 15ml falcon tubes, 
and then added to equal volumes of overnight culture of the respective organisms to achieve 
final concentrations that corresponded to 10%, 50% and 100% of the MIC that had been 
determined for each antibiotic and each isolate (Table A3, Appendix). 
The total volume inoculated into each well of the 96 well micro titre plate was 200μl; 
containing 100μl of overnight culture diluted 1:100 and 100μl of antibiotic in TSB as 
Stellenbosch University  https://scholar.sun.ac.za
   
62 
 
described above. Each 96 well plate allowed for assessment of biofilm formation of two 
isolates in the presence of all 4 antibiotics at the 3 concentrations. Figure 4.2 provides the 
layout of the 96 well plate, including technical triplicates for each concentration of each 
antibiotic, as well as control wells containing only culture in the absence of antibiotic, culture 
medium only (Negative control) and antibiotic in the absence of culture, to control for 
contamination of the culture media or antibiotic. Each assay was performed in biological 
triplicate. The average biofilm formation and standard deviation for each antibiotic 
concentration was calculated for each organism from the technical and biological replicates.  
Figure 4.2: 96 well micro titre plate layout for two different organisms.  Culture – 
organism with no antibiotic, AB – Antibiotic only (100% MIC), NEG – Sterile TSB with no 
antibiotic, PM – Cefepime, CI – Ciprofloxacin, IP – Imipenem, GM – Gentamicin. Antibiotic at 
10%, 50% and 100% of the MIC for the antibiotic / organism combination. 
 
Organism 1 Organism 2 
PM CI IP GM PM CI IP GM 
 A B C D E F G H 
1 Culture Culture Culture Culture Culture Culture Culture Culture 
2 10% 10% 10% 10% 10% 10% 10% 10% 
3 10% 10% 10% 10% 10% 10% 10% 10% 
4 10% 10% 10% 10% 10% 10% 10% 10% 
5 50% 50% 50% 50% 50% 50% 50% 50% 
6 50% 50% 50% 50% 50% 50% 50% 50% 
7 50% 50% 50% 50% 50% 50% 50% 50% 
8 100% 100% 100% 100% 100% 100% 100% 100% 
9 100% 100% 100% 100% 100% 100% 100% 100% 
10 100% 100% 100% 100% 100% 100% 100% 100% 
11 AB AB AB AB AB AB AB AB 
12 NEG NEG NEG NEG NEG NEG NEG NEG 
 
4.3 Results 
4.3.1 MIC determination 
The MICs of each of the antibiotics, cefepime, ciprofloxacin, imipenem and gentamicin, were 
determined for each of the 6 strains. For the purposes of categorisation of isolates as 
susceptible, intermediate or resistant,  the MIC was adjusted to the next doubling dilution if 
necessary, according to the performance standards for antimicrobial susceptibility testing 
(2015) (Table 4.1).  The MICs of isolates from the same MLVA type differed slightly, with the 
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exception of cefepime and gentamicin for MLVA type 1 and imipenem for MLVA type 2 
which had the same MIC. Cefepime, imipenem and gentamicin showed no more than a 2 
fold dilution difference in MIC between isolates of the same MLVA type. A single dilution 
difference is generally acceptable even when testing the same organism. On the other hand, 
ciprofloxacin showed much larger variation within the MLVA types with up to a 4 fold 
difference in MIC (adjusted MICs of 2 µg/ml vs 32 µg/ml for TBP 16 and TBP 23; and MICs 
of 16 µg/ml and 4 µg/ml for TBP 47 and 20 respectively). 
Table 4.1: Raw MIC and adjusted MIC results of six isolates including P. aeruginosa 
PAO1, determined for four antibiotics. S – Sensitive, I – Intermediate. R – Resistant. MIC 
values are given in µg/ml. 
  Cefepime Ciprofloxacin Imipenem Gentamicin 
MLVA 
Type 
Isolate 
Raw 
MIC 
Adjusted 
MIC 
Raw 
MIC 
Adjusted 
MIC 
Raw 
MIC 
Adjusted 
MIC 
Raw MIC 
Adjusted 
MIC 
Type 1 
TBP 47 3  4 (S) 12  16 (R)  8  8 (R) 256  256 (R) 
TBP 20 4  4 (S) 4  4 (R) 4  4 (I) 256 256 (R) 
Type 2 
TBP 16 4  4 (S) 1,5  2 (I) 6  8 (R) 256  256 (R) 
TBP 23 6  8 (S) 32  32 (R) 8  8 (R) 96  128 (R) 
Type 9 TBP 73 1 1 (S) 0.06  1 (S) 0.75  1 (S) 2  2 (S) 
Control PAO1 0.5  1 (S) 0.1  1 (S) 0.5  1 (S) 1.5  2 (S) 
 
Focussing on the categorical agreement (S, I, R), the results for isolates from MLVA type 1 
were identical except for the imipenem results for which TBP 20 and 47 were respectively 
intermediate and resistant, due to a single dilution difference in MIC. TBP 16 and 23, the 
MLVA type 2 isolates, were respectively intermediate and resistant to ciprofloxacin. All 
isolates selected were sensitive to cefepime, although the MICs for the isolates from MLVA 
types 1 and 2 were in some cases close to the breakpoint, and notably higher than the MICs 
of TBP 73 (MLVA type 9) and PAO1.  The same trend was observed for the susceptibility 
results to ciprofloxacin, imipenem and gentamicin, where the isolates from MLVA groups 1 
and 2 were all intermediate or resistant to these agents, while TBP 73 and PAO1 were 
susceptible. 
4.3.2 The effect of antibiotics on biofilm formation 
Biofilm formation of each of the 6 isolates was measured at 3 time points, 4, 10 and 24 
hours, in the presence of different concentrations of four different antibiotics and compared 
to the biofilm formation in the absence of antibiotics. Different time points were selected to 
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enable us to evaluate differences in how isolates react to antibiotics at different incubation 
periods.  
In the absence of antibiotic, two different patterns of biofilm formation were observed, which 
were independent of MLVA type (Figures 4.3 - 4.6). Isolates were either classified as early 
onset or late onset biofilm formers. TBP 47 (MLVA type 1) and 23 (MLVA type 2) were 
classified as early onset biofilm formers; with a strong biofilm present after 10 hours’ 
incubation (absorbance >1.0), followed by a decline in biofilm formation at 24 hours. The 
opposite was seen for TBP 20 (MLVA type 1), 16 (MLVA type 2) and 73 (MLVA type 9) 
which started with a weak biofilm at 10 hours, but showed a significant increase in biofilm 
formation by 24 hours; and were classified as late onset biofilm formers. The early and late-
onset biofilm formers corresponded to their classification as strong and weak biofilm forming 
strains, respectively (section 3.2.1). PAO1 did not display either of these patterns, with the 
amount of biofilm remaining relatively consistent across all 3 time points. 
Cefepime completely inhibited biofilm formation in late onset biofilm formers at all 
concentrations, although biofilm formation in TBP 73 was less affected than in TBP 20 and 
TBP 16 when exposed to cefepime at 10% of MIC. Interestingly TBP 73 also had a lower 
cefepime MIC than either of the other two late onset biofilm formers. PAO1, also susceptible 
to cefepime, showed far less effect of cefepime at any concentration, with the exception of a 
slight increase in biofilm at 10 hours when exposed to cefepime at 50% MIC. The isolates 
with early onset biofilm formation showed that cefepime concentrations of 50% of the MIC 
resulted in a late rise in biofilm formation (resulting in a pattern similar to a late biofilm 
forming isolate) while high concentrations of cefepime (100% of MIC) inhibited biofilm 
formation completely.  
Ciprofloxacin inhibited biofilm formation in all three late onset biofilm formers, up to 24 hours, 
at a concentration of 50% and 100% MIC. At 10% MIC, the antibiotic appeared to have less 
effect, and biofilm formation mirrored the control (more so for TBP 16 and TBP 73 than TBP 
20).  With regards to the early onset formers, at low concentrations (10% MIC), ciprofloxacin 
had little effect. However at higher concentrations (50% and 100% MIC), biofilm formation 
again resembled a “late onset biofilm” pattern, with relatively abundant biofilm at 24 hours in 
the presence of ciprofloxacin at 50% of the MIC. For PAO1, ciprofloxacin at all 3 
concentrations reduced the amount of biofilm present at all 3 time points, compared to the 
no-antibiotic control. 
Imipenem showed the least effect on biofilm formation, with the pattern of biofilm formation 
mainly mimicking the control growth curve at all three antibiotic concentrations. Again, PAO1 
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was an exception, with less biofilm present at all 3 time points, although more markedly so at 
both 4 and especially 10 hours. This closely mimicked the effect of ciprofloxacin on PAO1. 
Gentamicin at 100% of the MIC inhibited biofilm formation of the two gentamicin-resistant 
late onset biofilm formers (TBP 16 and TBP 20) compared to the gentamicin-susceptible late 
biofilm former (TBP 73). In contrast, lower gentamicin concentrations (10% and 50% MIC) 
appeared to result in biofilm patterns very similar to the antibiotic free control for all 3 late-
onset biofilm isolates. An increase in biofilm formation was seen at 24 hours for early onset 
biofilm formers exposed to gentamicin at 50% MIC. Conversely, at this time point the biofilm 
formation of both the antibiotic-free controls and isolates exposed to gentamicin at 10% MIC 
had reduced to almost baseline levels, with maximum biofilm seen at 10 hours. The only 
isolate where exposure to gentamicin at 50% of the MIC resulted in a reduction in biofilm at 
24 hours was the control strain, PAO1. 
All of the organisms were sensitive to cefepime while only the isolates that form an early 
biofilm (TBP 47, 23) showed biofilm formation at a 50 % MIC concentration. This occurrence 
can also be seen with the other antibiotics, where biofilm formation occurs at 50% MIC for 
both early biofilm forming strains.  
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Figure 4.3: Biofilm formation of isolates exposed to different concentrations of 
cefepime and incubated for 4h,10h and 24h. E – Early onset biofilm former, L – Late 
onset biofilm former. Control – No antibiotics. Y-axis: Absorbance (nm) X-axis: Incubation 
time (hours). 
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Figure 4.4: Biofilm formation of five isolates introduced to different concentrations of 
ciprofloxacin and incubated for different periods of time, 4h,10h and 24h. E – Early 
onset biofilm former, L – Late onset biofilm former.  Control – No antibiotics. Y-axis: 
Absorbance (nm) X-axis: Incubation time (hours). 
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Figure 4.5: Biofilm formation of five isolates introduced to different concentrations of 
imipenem and incubated for different periods of time, 4h,10h and 24h. E – Early onset 
biofilm former, L – Late onset biofilm former.  Control – No antibiotics. Y-axis: Absorbance 
(nm) X-axis: Incubation time (hours). 
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Figure 4.6: Biofilm formation of five isolates introduced to different concentrations of 
gentamicin and incubated for different periods of time, 4h,10h and 24h. E – Early onset 
biofilm former, L – Late onset biofilm former.  Control – No antibiotics. Y-axis: Absorbance 
(nm) X-axis: Incubation time (hours). 
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4.4 Discussion 
The aim of this study was to compare the effect of different antibiotics on different isolates 
with different biofilm formation abilities and belonging to different MLVA types. Two isolates 
each from MLVA type 1 and MLVA type 2 were chosen according to their biofilm forming 
abilities, as determined in chapter 3.  These two MLVA types were the most common among 
the isolates studied. One isolate from type 9 was included as a strain sensitive to all 
antibiotics, as there were no such susceptible isolates among those in MLVA type 1 or 2.  
Two biofilm formation patterns were observed amongst these isolates. Isolates previously 
chosen as weak biofilm formers were categorised in this chapter as late onset biofilm 
formers, while strong biofilm formers were categorised as early onset biofilm formers. In the 
first pattern, the biofilm formation initially seemed to be stationary followed by an increase in 
biofilm formation between 10 and 24 hours of incubation. The second pattern was 
characterised by early biofilm formation within the first 10 hours of incubation, followed by a 
decline in biofilm by 24 hours. These patterns were not unique to any MLVA type. 
Previously, in chapter 3, biofilm formation was only measured up to 12 hours, and it is 
possible that all the weak biofilm formers from the initial biofilm assays (chapter 3) are 
actually late onset biofilm formers; although this is small sample size from which to make 
such a generalisation. 
The response to antibiotics was similar amongst the early and late onset biofilm formers, 
respectively, even though they had different MLVA types. This might suggest that it is not the 
strain type that influences the effect of antibiotics on biofilm formation but rather the initial 
amount of biofilm, and therefore the rate at which a strain can form a biofilm.  
Imipenem had the least observable effect on biofilm formation with the growth curves in the 
presence of antibiotics mimicking the control growth curve. Cefepime and ciprofloxacin 
showed the greatest inhibition of biofilm formation at concentrations of 50% and 100% of the 
MIC. High concentrations of cefepime, ciprofloxacin and gentamicin appear to have very little 
effect on early onset biofilm formers while late onset formers are influenced more. A study 
from Brooun et al.,(2000)[128] focussed on the MexAB-OprM pump and showed cells did not 
show any difference in resistance to ciprofloxacin in the presence or absence of the MexAB-
OprM pump. The effect of gentamicin seems to show the most consistent pattern across all 
isolates and concentrations. Overall all, ciprofloxacin, imipenem and gentamicin at 
concentrations of 10% of the MIC had no effect on biofilm formation and mirrored the control 
growth curve (no antibiotic) which was probably due to the concentration being too low and 
not having any effect on the formation of the biofilm. Cefepime on the other hand inhibited 
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biofilm formation in late onset biofilm formers at an antibiotic concentration of 10% of the 
MIC. 
 
Some antibiotic sensitive strains were able to form biofilms when exposed to intermediate 
antibiotic concentrations such as TBP 47, 23 and 73 for cefepime, although concentrations 
equivalent to 100% of the MIC were able to inhibit biofilm formation, as was seen for 
resistant strains at 100% MIC. One might speculate that isolates that are resistant may be 
less affected by the antibiotic even at high concentrations since there is already a 
mechanism to counter the effect of the antibiotic activity such as MLVA types 1 and 2 for 
ciprofloxacin, imipenem and gentamicin, but this did not seem to be the case in this study. 
Comparing the isolates that are resistant to gentamicin with MICs of 256 µg/ml to those that 
are sensitive with MICs of 2 µg/ml, the antibiotic appeared to inhibit biofilm formation at 
100% MIC in the resistant strains, but not in the sensitive isolate (TBP 73) with a low MIC, 
despite the fact that a concentration equivalent to the MIC should by definition inhibit growth 
of the particular strain. This may be attributed to the limited ability of the biofilm to retard 
penetration of the antibiotic; at a low concentration of antibiotic there are sufficient 
antimicrobial binding proteins to bind all of the antibiotic, while for high antibiotic 
concentrations these proteins are unable to bind enough antibiotic to influence its activity.   
MLVA type 1 isolates which are resistant to ciprofloxacin and all isolates resistant to 
gentamicin still showed some biofilm formation (more than susceptible strains) at an 
antibiotic concentration of 50% but much less than expected from a resistant strain. 
Exposure to concentrations of 100% of the MIC did indeed have an impact on most isolates 
and stopped biofilm formation of the resistant strains completely, except for TBP 23 at 
gentamicin and TBP 47 at ciprofloxacin. One would expect a biofilm to be more resistant, 
since the biofilm will reduce the penetration of antibiotics to the cells which are already 
somewhat resistant, resulting in an even higher concentration needed to eradicate the 
organism completely; however this was not observed in this study. The effect of the antibiotic 
may have been different if the organism had been given a chance to form a biofilm before 
the antibiotic was added, as then the biofilm may have been able to restrict penetration of 
the antibiotic, or alter its activity in some way.[129]  
The mechanism of action of the antibiotic also appears to play little to no role in its effect on 
biofilm formation. Cefepime and ciprofloxacin, which have different mechanisms of action, 
showed similar effects on biofilm formation patterns, producing almost identical patterns. On 
the other hand, when looking at the results of exposure to cefepime and imipenem, which 
have the same mode of action, one would have expected similar effects on biofilm patterns; 
this was however not the case. This leaves us to question whether the mechanism of action 
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really does play a significant role. Not much is known about the impact of the mechanisms of 
antimicrobial action on the formation of biofilms. Since both ciprofloxacin and gentamicin 
display concentration dependant pharmacokinetics, one might expect greater inhibition of 
biofilm formation at higher antibiotic concentrations. However, this only holds true for late 
onset biofilm formers exposed to these antibiotics. On the other hand, β-lactams such as 
cefepime and imipenem show time dependant killing, and the longer the organisms are 
exposed to the drug the more inhibition will occur. This phenomenon was also more 
noticeable in late onset biofilm formers exposed to cefepime. 
Studies have shown that sub inhibitory concentrations of some antibiotics may promote 
biofilm formation and that organisms respond in a defensive manner[130]. A study done by 
Hoffman et al.,(2005) showed that sub inhibitory concentrations of aminoglycosides can 
induce biofilm formation in E. coli as well as P. aeruginosa and that the arr response 
regulator is responsible for this. This effect of sub inhibitory concentration was also observed 
in our study, for example we observed increased biofilm formation in early onset biofilm 
formers exposed to gentamicin and cefepime at an antibiotic concentration of 50% MIC. This 
may have clinical implications since patients receiving antibiotic treatment at sub inhibitory 
concentrations may be more likely to develop biofilm-related infections. Sub inhibitory 
concentrations of β-lactams such as imipenem have also been shown to enhance the 
production of EPS found in biofilms.[131] However, this did not seem to be true in our study 
since imipenem showed little to no effect on biofilm formation, and mimicked the control 
growth curve most of the time.  
A study similar to ours, but focusing on E. coli, showed that increasing concentrations of 
antibiotics, mainly imipenem and ciprofloxacin, caused high levels of cell death within a 
biofilm after the first few hours of incubation, where after a sub population emerged that was 
less susceptible and had the potential to expand.[128] They obtained similar results to those 
seen in our study for isolates treated with cefepime, ciprofloxacin and gentamicin; where 
initial biofilm formation was weak and slow when treated with 50% MIC concentration of 
antibiotics, followed by a sudden increase in formation after 10 hours of incubation. Our 
results show that antibiotics at concentrations of 100% MIC completely inhibited biofilm 
formation the majority of the time, suggesting that the initial concentration was high enough 
to inhibit or even kill the organisms (as per the definition of MIC), while the 50% 
concentration only kills the susceptible organisms leaving a sub population of less sensitive 
organisms that has the potential to reform a biofilm at a lower antibiotic concentration, as 
described in Figure 4.8. This was also described by Spoering at al.,(2001)[132] where low 
concentrations of fluoroquinolones were shown to have significant biofilm eradication effect, 
but what remained was a sub population of resistant cells with the potential of reforming a 
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biofilm. Again, the same was seen for ciprofloxacin in our study, although more noticeably 
for early onset biofilm formers than late biofilm formers. 
There are three ways that a biofilm can counter antibiotic activity and cause a persisting 
biofilm (Figure 4.7). Firstly, physically delaying of antibiotic penetration through the EPS, 
secondly, the persisting variant cells within a biofilm can be resistant to the antibiotics and 
thirdly, a sub population of slow growing cells can serve as a last resort for biofilm regrowth 
when all the sensitive and peripheral cells are eradicated, since these slow growing cells are 
not actively targeted by antibiotics.[95] 
Figure 4.7: Three ways in which  biofilms can develop 
resistance. Yellow – EPS delaying antibiotic penetration, Green – 
Persisting resistant cells, Red – Slow growing, metabolically 
slow/inactive organisms. Source: Stewart at al., (2001).[95] 
 
 
 
 
 
 
In our study we found that isolates from the same MLVA type did not show the same biofilm 
formation patterns and also did not have the same response to antibiotics. Studies have 
found that a population can contain phenotypic variants within a biofilm community in vivo 
and in vitro. These variants can be resistant to 106 fold higher levels of antibiotics and may 
cause a change in the response of a biofilm when treated with antibiotics.[133] Changes such 
as high surface hydrophobicity which will aid in cells attaching more easily to a surface result 
in increased biofilm formation. Phenotypic variants are common amongst Gram negative 
organisms and can be caused by environmental factors.[133]  This indicates that there is a 
connection between phenotypic variation and the ability of a biofilm to become resistant to 
antibiotic treatment.[133] These phenotypic changes have also been shown to occur in 
Staphylococcus aureus when exposed to gentamicin.[12]  
Two types of variants can be present within a biofilm; one is a phenotypic variant and the 
other a persister variant.[133] A phenotypic variant has the ability to grow in the presence of 
high concentrations of antimicrobials, but can be eradicated with prolonged treatment. 
Persister variants have the ability to withstand antibiotic eradication completely. A study has 
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shown that antibiotics are able to kill phenotypic variants effectively within a biofilm but when 
the dosage of antibiotics is increased there are still some cells that can survive and reform 
the biofilm, known as persister cells.[128][111] The same occurrence was found in our study at 
higher antibiotic concentrations. We saw that an increase in biofilm formation occurs at high 
concentrations of antibiotics particularly for gentamicin for both early (MLVA type 1 and 2) 
and late (MLVA type 9) onset biofilm formers which means there are still some cells that are 
able to grow after being exposed to an antibiotic. The process is explained in Figure 4.8. An 
initial biofilm will form and be eradicated by antibiotic treatment. A group of persister cells will 
remain unharmed and be able to form a mature biofilm resistant to antibiotics. These 
persister cells can emerge within 24 hours of biofilm formation triggered by malnutrition, a 
possible factor in our assay.[134][135] A study revealed that cells may have the same sensitivity 
to antibiotics when in a planktonic, stationary or biofilm state but high levels of resistance 
may remain due to the persister variants present within the community.[132] Cells deep within 
the biofilm (such as the persister cells) also have a limited supply of nutrients and oxygen 
which makes them metabolically slow or inactive, and antibiotics will target more 
metabolically active cells. It has been speculated that this phenomenon can decrease the 
susceptibility of a biofilm to antibiotics.[129] Slow growing P. aeruginosa cells have also been 
shown to be less affected by β-lactams, while growth rate does not show any significant 
impact on the effectiveness of fluoroquinolones.[136] Further studies will have to be done to 
establish whether incubation time may influence the results. 
 
Figure 4.8: Mechanism of antimicrobial resistance in a bacterial biofilm. Antimicrobial 
treatment is effective against the peripheral areas of the biofilm while a sub population in the 
middle remains resistant against antibiotic treatment. Source: Drenkard (2003).[12] 
An interesting observation revealed that cells within a biofilm are not mutants of the parental 
strain and that these cells, when isolated from a resistant biofilm and exposed to antibiotics 
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have the same MIC results as to the original inoculated strain.[128] This indicates that the 
physical protection of a biofilm does in fact play a significant role in cells being resistant. On 
the other hand, a study by Brooun et al.,(2000)[128] compared planktonic cells to cells isolated 
from a biofilm, and showed that the cells isolated from the biofilm are more resistant, 
implying that cells become intrinsically more resistant. Furthermore, a study from Liao and 
Sauer revealed that a transcriptional regulator brIR plays a major role in the in the antibiotic 
susceptibility of P. aeruginosa biofilms to multiple antibiotics and also regulates the 
expression of the MexAB-OprM efflux pump.[137] 
 
Studies have shown that the penetration rate of antibiotics such as aminoglycosides 
(gentamicin) is reduced in P. aeruginosa biofilms, while fluoroquinolones such as 
ciprofloxacin can penetrate a biofilm without any delay.[138][139] Delayed penetration of an 
antibiotic can be due to embedded transport molecules binding the antibiotic molecules.[12] 
This is not consistent with our findings, with respect to gentamicin. Gentamicin seemed to 
inhibit the formation of the biofilm within the first 10 hours, regardless of the concentration, 
where after a sudden increase in biofilm formation occurred in isolates exposed to 
concentrations of 50% MIC while a concentration of 100% MIC inhibits biofilm formation. 
This was particularly marked for the early biofilm forming isolates. Based on an assumption 
of delayed penetration of gentamicin, one would have expected ongoing biofilm formation 
within the first few hours followed by a steady decline in biofilm formation. Our results are 
however consistent with the finding that ciprofloxacin can penetrate the biofilm without delay, 
since minimal biofilm formation occurred during the initial 12 hour incubation period, implying 
that ciprofloxacin takes immediate action. This suggests that resistance in biofilms is not only 
related to embedded transport molecules, but that other factors might also play a role.  
These changes can cause stress and result in antimicrobial resistance. Stress factors 
include nutrition depletion, damaged DNA, and basic environmental factors such as 
temperature, osmotic and oxidative changes.[12] It has been shown that some antimicrobials 
penetrate a biofilm easily and reach the cells but still fail to kill the cells within the biofilm, 
indicating that the cells within the biofilm are still more resistant to the antimicrobial than 
planktonic cells and again suggests that resistance is not only dependant on the limited 
transport within a biofilm.[140] Biofilms delaying the diffusion of antibiotics will not save the 
bacteria from being killed but rather postpone the action of the antibiotic. 
Limitations in this study include that only the formation of a biofilm was measured and not 
the planktonic growth. Free floating cells within the wells could be a good indication of 
whether the antibiotics are killing the planktonic cells and thereby preventing formation of a 
biofilm,  inhibiting biofilm formation or breaking down the biofilm; as well as whether there is 
a difference in resistance between planktonic and biofilm cells. However, Spoering et 
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al.,(2001) showed that biofilms do not show differences in resistance to growth inhibition 
compared to planktonic cells but rather to antibiotic killing.[132] Growth and formation of a 
biofilm seems to be as sensitive to antibiotics as planktonic cells. Additional experiments can 
be performed to determine the effects of antibiotics on already formed biofilms. Furthermore, 
the number of time points selected for the study could be increased to determine more 
accurate changes occurring during the development of a biofilm. The sample set used in this 
study was relatively small and failed to include a large range of isolates representing 
different antibiotic susceptibilities. The stability of the antibiotics is also unknown and can be 
further studied to determine optimal and sustainable concentrations for use in biofilm 
studies.  
4.5 Conclusion 
Previously in chapter 3 we found that isolates within the same MLVA type had different 
biofilm forming abilities at a single time point. In this chapter, we observed that isolates 
within the same MLVA type also have different biofilm growth rates. This might suggest that 
it is not the MLVA type that influences the effect an antibiotic has on the formation of a 
biofilm but rather the initial rate at which a biofilm is formed. All of the antibiotics had a 
noticeable effect on biofilm formation after about 10-12h incubation. Varying concentrations 
of antibiotics appeared to influence the biofilm formation of the different isolates in different 
ways. The most noticeable inhibition of biofilm formation was by cefepime and ciprofloxacin. 
It was observed that organisms with an early onset biofilm formation pattern were impacted 
less than late onset biofilm formers by the addition of antibiotics. The mechanism of action of 
the antibiotic did not seem to play a major role since antibiotics that have different 
mechanisms of action showed similar effects on inhibition patterns. Establishing the nature 
of an isolate’s biofilm forming ability may help with the early and rapid eradication of a biofilm 
associated infection. 
Antibiotic resistance in P. aeruginosa is an increasing concern which affects many people 
daily. It is important to understand the effects of antibiotics on biofilm formation and 
breakdown. It remains to be determined whether the physical delaying of penetration and 
binding of antibiotics are the primary mechanisms of resistance of the biofilm, or whether 
persisting cells within the biofilm play a bigger role. Studies on persisting cells within the 
biofilm will assist in determining how to eradicate these cells. Further research in developing 
new antibiotics, and techniques such as combining antibiotics for more efficient treatment of 
biofilm related infections, can assist in fighting recurring chronic infections. 
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Chapter 5 
5.1. Conclusion 
 
Pseudomonas aeruginosa is an opportunistic pathogen which commonly infects patients 
with a compromised immune system and is often associated with biofilm formation.[4] The 
ability to form a biofilm provides an advantage to the organism, by enabling it to withstand 
the effects of antibiotics through the physical protection of the surrounding 
extrapolysaccharide matrix. P. aeruginosa infections are a common and growing occurrence 
in the clinical setting.[5] Nosocomial transmission is an expanding problem, particularly in the 
burns unit. Biofilm formation within this patient group has not been described, but  P. 
aeruginosa is commonly associated with biofilm formation.[111] It is important to understand 
the epidemiology of the organism, its ability to form biofilms and the effect of antibiotics on 
the formation of biofilms for rapid detection, treatment and eradication. 
In this study we have described the genetic relatedness of P. aeruginosa isolates found in 
the burns unit and burns ICU (burns unit/ICU) compared to other wards within Tygerberg 
hospital by means of MLVA (Multiple locus variable number tandem repeat analysis). We 
have identified a number of MLVA types within as well as outside the burns unit/ICU. Forty 
two different MLVA types were identified, of which 10 MLVA types were shared by two or 
more isolates. The remaining 32 MLVA types had unique MLVA patterns. MLVA type 1 had 
the most isolates, all of which were isolated from the burns unit/ICU, with the exception of 
one isolate which came from a different ward. MLVA type 1 isolates accounted for 60% of 
the burns isolates, suggesting that spread within the burns unit/ICU occurs regularly. Four 
other MLVA types containing two or more isolates were identified in the burns unit/ICU; of 
which MLVA type 2 was the most abundant, with four isolates. Outside of the burns unit, 
seven MLVA types were identified, with a maximum of 3 isolates per MLVA type, indicating 
more strain diversity, which may be due to less transmission occurring in other parts of the 
hospital. From our study it is clear that there is a need for better infection prevention control 
within the burns unit/ICU at Tygerberg Hospital, and these results have been communicated 
to the IPC (Infection prevention control unit). 
We further investigated the biofilm formation ability of the P. aeruginosa isolates from the 
burns unit/ICU as well as outside the burns unit/ICU. Biofilm assays were performed to 
identify the optimal incubation period to assess biofilm formation. A clear change in biofilm 
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formation was seen at 10-12 hour incubation. Three different biofilm formation patterns were 
described in our study, namely noticeable increase in biofilm formation, no noticeable 
increase, and an increase in biofilm followed by dispersion. There were similar numbers of 
strong biofilm forming (40%) and weak biofilm forming (55%) isolates amongst the burns 
isolates, however the majority of non-burn isolates were strong biofilm formers (72%). The 
biofilm formation abilities of isolates from different specimen types were also compared, and 
the majority of isolates from wound/pus swabs, tissue samples and sputum samples were 
shown to be strong biofilm formers. Further investigations need to be performed since the 
small sample set made comparisons difficult. Furthermore, the biofilm formation of the 
different MLVA types was compared. No similarity in biofilm formation ability was identified 
between isolates within the same MLVA type, indicating that multiple factors play a role in 
the ability of an isolate to form a biofilm. 
Organisms within a biofilm have been shown to be more resistant to antibiotics than 
planktonic cells.[12] In this study we investigated the effect of common Gram negative 
antibiotics on the ability of an isolate to form a biofilm. Four antibiotics from different 
antibiotic classes and with different mechanisms of action were included in this study. A 
subset of isolates was selected from different MLVA types based on their ability to form a 
biofilm, and their biofilm formation determined over 24 hours in the presence of three 
different concentrations of each antibiotic.  Similar to what was seen when observing biofilm 
formation at a single time point, no similarity in biofilm formation was observed in isolates 
from the same MLVA type in the presence of antibiotics. Based on the observed biofilm 
formation patterns, two types of biofilm formers were identified; early and late onset biofilm 
formers. Isolates which were defined as having the ability to form either a strong or weak 
biofilm (chapter 3) could be classified as early or late onset biofilm formers, respectively. 
Isolates within the same MLVA type could be either early or late onset biofilm formers, 
suggesting that MLVA type does not play a significant role in defining the biofilm response of 
an isolate when exposed to antibiotics. Some similarity could be seen between early onset 
and late onset biofilm formers respectively. Early onset biofilm formers appeared to have 
better biofilm forming ability in the presence of antibiotics compared to late onset biofilm 
formers which were more affected by antibiotics.  The mechanisms of action of the 
antibiotics did not appear to affect the biofilm formation response. Two antibiotics, cefepime 
and ciprofloxacin, which have different mechanisms of action showed similar biofilm 
inhibition patterns, while cefepime and imipenem, which have similar mechanisms of action, 
evoked very different responses. Sub inhibitory concentrations of antibiotics enhanced 
biofilm formation in some isolates, consistent with previous reports that sub inhibitory 
concentrations of antibiotics given to patients can enhance biofilm related infections and 
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should be avoided.[130] Based on our results we speculate that the ability of an organism to 
withstand antibiotics and show an increase in biofilm formation relies on the initial amount of 
biofilm the organism are able to form within the first 10 hours of incubation, in the presence 
of the antibiotic. A factor that could influence this is the stability of the antibiotic and therefore 
concentration in the assay over time.  
P. aeruginosa has been shown to be a promising model organism for biofilm formation 
assays and studying the antibiotic susceptibility of forming biofilms. The epidemiology of this 
organism was determined within the burns unit/ICU to better inform infection prevention 
control measurements within the hospital. An enhanced understanding of the P. aeruginosa 
population structure and biofilm formation ability in this patient group and the impact 
antibiotic treatment on the establishment of biofilms may enable improvements in 
transmission prevention and clinical treatment and outcome.  
5.2 Limitations 
 
Our study used thirteen locus MLVA typing, which has been reported to provide sufficient 
discriminatory power; however two loci, ms207 and ms209 were excluded from the study 
since the product sizes of these loci are difficult to score. Although these loci are regularly 
excluded from studies, they have been shown to provide additional discriminatory power 
which could influence the typing results. 
Certain isolates showed large standard deviations between biological replicates in the biofilm 
assays. A number of factors could have influenced this observation. Organisms may behave 
differently on different days based on small changes in the environment, secondly organisms 
tend to behave differently at different stages of biofilm formation[119], and thirdly the staining 
technique that we have used, namely crystal violet staining, has previously been reported to 
cause variation during biofilm staining.[112] Overall, crystal violet staining may not be the best 
choice of stain for the quantification of P. aeruginosa biofilms, but it remains a common, 
rapid, easy and cheap method. 
When investigating the effect of antibiotics on biofilms in our study we did not determine the 
amount of planktonic cells that were present. These cells could provide an indication of 
whether the antibiotics are killing the cells or merely inhibiting or breaking down the biofilm. 
Furthermore, these planktonic cells could also indicate whether cells within the biofilm are 
more resistant than these free floating cells.  The assay was performed on developing 
biofilms and not the exposure of already formed biofilms to antibiotics, which may have 
different results. Mature biofilms may have better resistance mechanisms in place, such as 
physically delaying penetration. 
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5.3 Future direction 
 
Further studies can include validation of the discriminatory power of the MLVA typing 
scheme in our setting and investigating the possible reasons why similar strain types have 
different biofilm formation abilities and different reactions to antibiotics during biofilm 
formation. This can be done by comparing MLVA to a well-established typing method such 
as PFGE (pulsed field gel electrophoresis), MLST (Multiple locus sequence typing) or whole 
genome sequencing. A larger sample set of P. aeruginosa isolates from different wards 
within Tygerberg can also be studied to cover a wider range of infections, and to study 
transmission patterns in other wards of the hospital more reliably.  
Further assays comparing cells within a biofilm and free floating viable cells outside the 
biofilm can assist in explaining the different biofilm formation patterns that have been 
described. This can then also be compared to mature biofilms exposed to antibiotics since 
the physical barrier of a mature biofilm can have an influence on antibiotic penetration. 
Additional experiments can be performed using an alternative biofilm and planktonic 
quantification methods, since P. aeruginosa showed large standard deviations when using 
crystal violet staining. Alternative methods such as the Syto9, FDA (fluorescein diacetate), 
resazurin, XTT and dimethyl methylene blue assays can be used as alternative for biofilm 
and planktonic cell quantification. 
Proteomic studies would allow us to investigate the proteins involved in biofilm formation in 
the presence and absence of antibiotics. The different mechanisms of action that antibiotics 
have and the stability of antibiotics within the assay should also be further investigated to 
identify possible factors influencing biofilm formation. 
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Table A1: MLVA typing of P. aeruginosa isolates from patients in the burns unit at Tygerberg hospital: * - represents unique MLVA type, NA-no amplification 
Sample #  ms77 ms127 ms172 ms142 ms211 ms212 ms214 ms215 ms216 ms217 ms222 ms223 ms213 Type 
Pseudo 3 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 4 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 7 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 9 2,5 8 11 4 8 11 4 1 2 3 1 2 1 3 
Pseudo 11 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 12 2,5 8 11 4 8 11 4 1 2 3 1 2 1 3 
Pseudo 13 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 14 3 9 13 1 7 0.5 4 0.25 1 5 1 4 6 2 
Pseudo 15 3 9 13 1 3 9 NA 0.25 1 5 1 4 6 1 
Pseudo 16 3 9 13 1 7 0.5 4 0.25 1 5 1 4 6 2 
Pseudo 17 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 18 3 NA 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 19 2 8 10 1 2 6 4 1 1 4 2 2 3 5 
Pseudo 20 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 21 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 22 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 23 3 9 13 1 7 0.5 4 0.25 1 5 1 4 6 2 
Pseudo 24 3 9 13 1 7 0.5 4 0.25 1 5 1 4 6 2 
Pseudo 25 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 26 3 9 13 1 3 9 NA 0.25 1 5 1 4 6 1 
Pseudo 27 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 28 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 29 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 30 1 9 12 1 2 4 5 2 1 5 2 4 1 * 
Pseudo 31 1 9 11 1 5 9 5 2 1 2 1 4 5  * 
Pseudo 32 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 33 3 8 14 4 3 6 5 5 2 4 3 7 9  * 
Pseudo 34 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 35 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 42 4 9 13 1 3 9 4 0.25 1 5 1 4 5,5 6 
Pseudo 43 4 9 13 1 3 9 4 0.25 1 5 1 4 5,5 6 
Pseudo 44 3 8 11 4 5 NA 5 1 2 3 1 2 0  * 
Pseudo 45 4 9 13 1 3 9 4 0.25 1 5 1 4 5,5 6 
Pseudo 47 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 54 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 55 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 56 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 57 2 8 8,5 7 7 11 6 4 2 1 2 4 3  * 
Pseudo 58 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 59 2 9 10 3 7 5 4 4 1 1 4 3 3  * 
PAO1 4 8 12 7 5 9 3 4 3 2 2 4 5 Control 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
   
84 
 
Table A2 MLVA typing of P. aeruginosa isolates from patients outside the burns unit at Tygerberg hospital: * - represents unique MLVA type, NA-no amplification 
Sample #  ms77 ms127 ms172 ms142 ms211 ms212 ms214 ms215 ms216 ms217 ms222 ms223 ms213  Type 
Pseudo 1 2,5 8 12 2 3 8 5 6 1 4 1 2 4 4 
Pseudo 2 4 9 11 1 7 4 4 2,5 2 5 1 3 4  * 
Pseudo 5 2,5 8 12 4 8 9 2 4 2 4 3 3 2  * 
Pseudo 6 2,5 8 8 3 8 6 2 1 2 1 1 1.125 5  * 
Pseudo 8 2,5 8 12 2 3 8 5 6 1 4 1 2 4 4 
Pseudo 10 2,5 8 11 6 7 3 3 2 1 3 1 2 5,5  * 
Pseudo 36 3 9 13 1 3 9 4 0.25 1 5 1 4 6 1 
Pseudo 37 3 8 9 5 3 9 2 4 2 3 2 4 7  * 
Pseudo 38 3 8 11 12 6 3 3 2 1 3 1 2 4,5  * 
Pseudo 39 3 8 12 2 3 8 5 5 1 3 1 2 4  * 
Pseudo 40 1 8 11 4 5 NA 4 3 IS 3 4 7 2  * 
Pseudo 41 3 8 12 4 9 9 2 4 2 4 3 3 1 * 
Pseudo 46 1 8 11 5 7 NA NA NA 3 2 4 IS 5  * 
Pseudo 48 2 8 NA 5 6 14 5 1 4 3 7 2 3.5  * 
Pseudo 49 3 9 10 4 2 6 2 1 2 2 1 3 1  * 
Pseudo 50 3 8 12 4 8 9 2 4 2 4 3 3 2 * 
Pseudo 51 3 8 8 3 8 6 2 1 2 1 1 1.125 4  * 
Pseudo 52 3 8 10 6 3 7 4 4 1 2 1 5 3  * 
Pseudo 53 2 9 12 1 2 4 5 2 1 5 2 4 1 * 
Pseudo 60 2 8 11 5 4 6 2 1 2 2 1,5 2 5 7 
Pseudo 61 2 8 11 5 2 7 4 4 2 3 NA 2 5  * 
Pseudo 62 2 8 11 5 4 6 2 1 2 2 1,5 2 5 7 
Pseudo 63 2 8 11 4 8 11 4 1 2 3 1 2 1 8 
Pseudo 64 3 9 NA 1 NA 3 NA 0.25 1 6 1 4 6 * 
Pseudo 65 2 8 11 4 7 9 4 5 2 2 2 2 5,5 *  
Pseudo 66 2 8 11 4 8 11 4 1 2 3 1 2 1 8 
Pseudo 67 2 8 9 3 6 6 2 4 2 1 1 5 4,5  * 
Pseudo 68 6 8 13 1 2 9 5 1 1 2 3 3 1  * 
Acineto 69 NA NA 13 4 NA NA NA 66bp 0 NA 2 NA NA  * 
Pseudo 70 2 8 10 1 2 6 4 1 1 4 2 2 3 5 
Pseudo 71 2 8 11 4 7 6 3 2 1 1 3 4 4 * 
Pseudo 72 2 8 11 6 6 3 3 2 1 3 1 2 5 * 
Pseudo 73 2 8 12 4 8 9 2 4 2 4 3 3 2 9 
Pseudo 74 2 8 11 4 8 11 4 1 2 3 1 2 1 8 
Pseudo 75 2 8 12 4 8 9 2 4 2 4 3 3 2 9 
Pseudo 76 3 9 13 1 3 3 4 0.25 1 5 1 4 6 10 
Pseudo 77 4 8 8 3 2 9 3 1 2 4 2 2 5,5 *  
Pseudo 78 2 8 11 3 3 9 5 2 2 4 2 2 7 *  
Pseudo 79 3 8 12 1 3 9 5 2 1 3 2 2 5 * 
Pseudo 80 3 9 13 1 3 3 4 0.25 1 5 1 4 6 10 
PAO1 4 8 12 7 5 9 3 4 3 2 2 4 5 Control 
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Table A3: Antibiotic dilutions for 10%, 50% and 100% isolate MICs. Cefepime, 
Ciprofloxacin, Imipenem and Gentamicin. Formula: C1V1=C2V2  
Stock in H2O In TSB Dilutions  
Cefepime 
Stock 12,8 
mg/ml 32 μg/ml 16 μg/ml 12 μg/ml 8 μg/ml 6 μg/ml 4 μg/ml 
3 
μg/ml 
  
How to 
prepare 
25μl stock 
in  
10ml TSB 
12,5μl 
stock in  
10ml TSB 
3,75ml 32 
in  
6,25ml TSB 
5ml 16 in  
5ml TSB 
1,875ml 
32 in  
8,125ml 
TSB 
5ml 8 in  
5ml TSB 
5ml 6 
in  
5ml 
TSB 
  
   
1,2 μg/ml 0,8 μg/ml 
0,6 
μg/ml 
    
 
  
1ml 12 in  
9ml TSB 
1ml 8 in  
9ml TSB 
1ml 6 in  
9ml TSB 
    
          Ciprofloxacin 
Stock 16 
mg/ml 64 μg/ml 32 μg/ml 24 μg/ml 12 μg/ml 
16 
μg/ml 8 μg/ml 
4 
μg/ml 3 μg/ml 
1,5 
μg/ml 
How to 
prepare 
40μl stock 
in  
10ml TSB 
20μl stock 
in 10ml 
TSB 
3,75ml 64 
in  
6,25ml TSB 
5ml 24 in  
5ml TSB 
5ml 32 
in  
5ml TSB 
5ml 16 in  
5ml TSB 
5ml 8 
in  
5ml 
TSB 
1,875ml 
16 in  
8,125ml 
TSB 
5ml 3 in  
5ml TSB 
 
6,4 μg/ml 
 
2,4 μg/ml 
  
0,8 μg/ml 
 
0,3 μg/ml 
 
 
1ml 64 in  
9ml TSB 
 
1ml 24 in  
9ml TSB 
  
1ml 8 in  
9ml TSB 
 
1ml 3 in  
9ml TSB 
 
          Imipenem 
    Stock 5 mg/ml 16 μg/ml 12 μg/ml 8 μg/ml 6 μg/ml 4 μg/ml 
    
How to 
prepare 
32μl stock 
in  
10ml TSB 
24μl stock 
in  
10ml TSB 
16μl stock 
in  
10ml TSB 
5ml 12 in  
5ml TSB 
5ml 8 in  
5ml TSB 
    
 
1,6 μg/ml 1,2 μg/ml 0,8 μg/ml 
      
 
1ml 16 in  
9ml TSB 
1ml 12 in  
9ml TSB 
1ml 8 in  
9ml TSB 
      
          Gentamicin 
     Stock 25,6 
mg/ml 512 μg/ml 256 μg/ml 192 μg/ml 96 μg/ml 
     
How to 
prepare 
200μl stock 
in  
10ml TSB 
5ml 512 in  
5ml TSB 
75μl stock 
in  
10ml TSB 
5ml 192 
in  
5ml TSB 
     
 
51,2 μg/ml 
 
19,2 μg/ml 
      
 1ml 512 in  
9ml TSB 
 
1ml 192 in  
9ml TSB 
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